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Abstract 
 
The Rise and Stall of the Lake Nona Biotech Cluster 
 
Jessica L. Snyder, M.P.Aff., M.B.A. 
The University of Texas at Austin, 2016 
 
Supervisor:  William Spelman 
 
Following the commitment of the new College of Medicine to locate at Lake Nona, 
the development of “Medical City” at Lake Nona officially began. The impact of the new 
cluster was expected to be quick and substantial. A decade later, policymakers and the 
public are largely disappointed by the lackluster impact of the Lake Nona cluster. This 
paper aims to understand how and why Medical City at Lake Nona has failed to meet 
expectations and whether there is hope for the industrial cluster to regain traction and 
achieve the success once envisioned.  
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Chapter 1: Introduction 
This chapter will provide background on Medical City at Lake Nona, discuss the objective 
of the paper, and detail the approach and methodologies used to arrive at conclusions. 
 
BACKGROUND 
In 1996 the Tavistock Group purchased 7,000 acres in Orlando, Florida and 
immediately began developing a master planned community called The Villages at Lake 
Nona. By 2003, however, Joe Lewis – the owner of Tavistock Group – was determined to 
use the land in a highly impactful and commercial manner. In light of a recent statewide 
efforts under Governor Jeb Bush to promote the biomedical industry, the Tavistock Group, 
along with local policymakers, decided to seed an industrial cluster at Lake Nona focused 
on the biotechnology and life science industries. In 2005, Tavistock donated 50 acres and 
$12.5 million to the recently approved UCF College of Medicine. Following the 
commitment of the new College of Medicine to locate at Lake Nona, a number of other 
prominent biotech firms agreed to locate in the community as well, effectively launching 
the development of “Medical City” at Lake Nona..  
The impact of the new cluster was expected to be quick and substantial. By 
attracting large and established biotechnology companies such as the Sanford Burnham 
Institute, policymakers assumed they could fast forward the development of the industrial 
cluster. It was an idealistic and optimistic goal. It was expected that established research 
partners would continue to conduct innovative basic research, UCF and the College of 
Medicine would supply critical human capital, that functional partners (such as the 
Veterans Affairs research hospital) would provide an important conduit for translation 
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research, and that venture capitalists excited by the developments would fund spin-off 
companies dedicated to commercializing Lake Nona’s research.  
A 2006 study by the Milken Institute estimated that the industrial cluster (largely 
dependent upon the success of the College of Medicine) would create an additional $6.4 
billion in economic impact by 2017 (roughly the 10th year of the operational phase of the 
new college).1 Public expectations for the development were also substantial, and the 
development of Medical City was repeatedly compared to that of Walt Disney. 
 Ten years after the Milken Study and six years since Sanford Burnham and the 
College of Medicine opened their doors at Lake Nona, policymakers and the public are 
largely disappointed at the lackluster impact of the Lake Nona cluster. Many key partners 
have been delayed in opening their doors, employment commitments made by companies 
in return for state and local subsidies have not been achieved, no spinoffs have resulted 
from research efforts at the cluster, innovation through basic research has been minimal, 
and Florida has not succeeded in attracting greater degrees of venture capital. 
 
OBJECTIVE 
Although articles have been written criticizing the stalled development of Medical City, 
little research has been dedicated to exploring that reason for its lackluster performance. 
This paper aims to understand how and why Medical City at Lake Nona has failed to meet 
expectations and whether there is hope for the industrial cluster to regain traction and 
achieve the success once envisioned. 
 
                                                 
1 Wong, Perry, and Armen Bedroussian. "Economic Benefits of Proposed University of Central Florida 
College of Medicine." Santa Monica, CA: Milken Institute (2006). 
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APPROACH 
This paper begins by providing a background and history of the envisioned cluster 
at Lake Nona. Next, qualitative case studies of successful U.S. biotechnology clusters are 
conducted with the goal of applying lessons learned from their development towards the 
case at Lake Nona.  
The reminder of the paper – Chapters 4 through 7 – considers elements which are 
considered key for the development of a successful biotechnology and life science cluster, 
including: 
 
 Funding. Biotechnology is a high-cost industry and unique with respect to its 
dependence on both basic research funding (provided by NIH) and translational 
research funding (often provided by venture capitalists) to succeed. Chapters 4 
and 5 analyze recent trends in NIH funding and venture capital to understand 
how these trends may have impacted development efforts at Lake Nona. 
 The strength of anchor institutions.  Anchor institutions are often responsible 
for promoting the development of an industrial cluster by providing expertise, 
networking opportunities, and bolstering the reputation of a cluster. Academic 
institutions often serve as important anchor institutions in high technology 
clusters. As reflected in the frequently cited 2006 Milken Institute report, the 
UCF College of Medicine was largely regarded as such an academic anchor for 
Lake Nona. The successes and challenges of the college are analyzed in Chapter 
6. Given the weakness of the college to date, the strength of UCF more broadly 
is analyzed in Chapter 7 in order to understand how the university would have 
compensated for the weak College of Medicine to support Lake Nona’s 
development. 
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Information was collected from reputable academic and news sources, as well as from one-
on-one interviews with academics knowledgeable of local economic development issues 
in North Central Florida.  
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Chapter 2: The Rise and Stall of Lake Nona 
This chapter attempts to introduce and give background to the Lake Nona cluster by: 1) 
defining the biotechnology industry and introducing the idea of a cluster; 2) explaining 
rationale and efforts to promote the biotechnology industry in Florida; 3) describing the 
establishment of Lake Nona and its initial successes, and; 4) discussing controversy 
surrounding its stalled performance. 
 
BIOTECHNOLOGY IN THE U.S. 
Biotechnology can be defined as the study and application of molecular and cellular 
processes to produce technologies which address human needs. Although the majority of 
the biotech industry is focused on human healthcare, many companies apply their research 
to develop products and services for agricultural productivity, food processing, industrial 
manufacturing, renewable resources, animal health, and environmental management. The 
biotechnology industry arose following the discovery of DNA in 1953 and experienced 
explosive growth following the discovery of recombinant DNA in 1973. According to IBIS 
World, the U.S. biotechnology industry consisted of 2,138 businesses, generated $109 
billion in revenues and employed over 216,000 people in 2014. 
Biotechnology firms tend to agglomerate in distinct geographic areas along with 
other businesses in the life science industries.2 Such an agglomeration of interrelated 
industries is often referred to as a cluster. An industry cluster can be defined as a “group 
of similar and related firms in a defined geographic area that share common markets, 
technologies, worker skill needs, and which are often linked by buyer-seller 
                                                 
2 The Milken Institute defines the “life sciences” as encompassing six major industries: pharmaceuticals, 
biotechnology, life sciences R&D, medical devices, health-care services, and supporting industries. 
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relationships.”3 Clusters consist of companies, suppliers, and service providers, as well as 
government agencies and other institutions that provide specialized training and education, 
information, research and technical support.4 Figure 1 provides an illustrative anatomy of 
the biopharmaceuticals industry in Boston, Massachusetts as developed by the U.S. Cluster 
Mapping Project.  
 
Figure 1: The Boston Biopharmaceuticals Cluster 
 
 
Source: U.S. Cluster Mapping Project, Institute for Strategy and 
Competitiveness, Harvard Business School. 
 
                                                 
3 "Industry Clusters FAQ." Oregon Business Plan. Web. 1 Mar. 2016. 
4 "Clusters 101." U.S. Cluster Mapping. Harvard Business School. Web. 1 Mar. 2016.  
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Table 1 below identifies top U.S. biopharma clusters based on total industry 
employment. The location quotient, or share of local employment in an industry relative to 
the national average, is also provided.5 
 
Table 1: Top 10 U.S. Biopharma Clusters in 2013 by Total Employment 
Rank MSA Total Employment Location Quotient 
1 New York, NY 24,984 1.73 
2 Chicago, IL 18,298 2.11 
3 Los Angeles, CA 14,586 1.30 
4 San Francisco, CA 13,801 3.43 
5 Philadelphia, PA 10,930 2.08 
6 Boston, MA 8,971 1.76 
7 San Diego, CA 6,578 2.76 
8 St. Louis, MO 4,250 1.49 
9 Raleigh, NC 3,950 4.65 
10 Grand Rapids, MI 3,760 3.95 
Source: U.S. Cluster Mapping Project, Institute for Strategy and Competitiveness, 
Harvard Business School. 
 
POLICY DRIVEN BIOTECHNOLOGY IN FLORIDA 
The success of high-profile industrial clusters like Silicon Valley has prompted 
many local leaders to seed entrepreneurial clusters within their regions. Policy makers 
justify such interventions by claiming that new firms promote positive economic growth 
and help to fight local poverty, and that imperfect credit markets would prevent these firms 
from ever locating to their region without government incentives.6  
                                                 
5 The location quotient is an index for comparing employment in a particular industry relative to that of the 
national share. A location quotient greater than 1.0 has a higher concentration industry employment relative 
to the United States as a whole. 
6 Chatterji, Aaron, Edward L. Glaeser, and William R. Kerr. Clusters of entrepreneurship and innovation. 
No. w19013. National Bureau of Economic Research, 2013. 
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The promotion of the biotechnology industry has been a particularly competitive 
area of economic development at the state level, and under Governor Jeb Bush Florida 
developed one of the most aggressive plans to promote attract biotechnology businesses.7 
In 2003, Bush passed a $310 million incentive package to entice the California-based 
Scripps Research Institute to expand into Jupiter, Florida. Palm Beach County approved 
an additional $203 million in local subsidies to close the deal. This marked the beginning 
of a concerted policy effort by the Bush administration to promote and develop the biotech 
industry in Florida.  In addition to high-paying jobs directly created by the recruited biotech 
research institutes, commercialization of their scientific discoveries was expected to result 
in a number of spin-off companies, attracting venture capital and other biotechnology 
companies to the state. 
In 2006, in his last year as governor, Jeb Bush approved the creation of the 
Innovation Incentive Program (IIP) within the Department of Economic Opportunity 
(DEO) to “ensure that sufficient resources are available to allow the state to respond 
expeditiously to extraordinary economic opportunities and to compete effectively for high-
value research and development, innovation business, and alternative and renewal energy 
projects.”8 Research and development entities, innovative businesses, and alternative and 
renewable energy companies are eligible to apply for program funds.  
To qualify for the program, an applicant must agree to pay an average wage 
equaling at least 130% of the average private sector wage. All recipients must meet agreed-
upon performance measures in order to receive funding, and – as of 2009 – reinvest up to 
                                                 
7 Weintraub, Arlene. "Jeb Bush's Big Biotech Push." Bloomberg. 11 Apr. 2006. Web. 1 Mar. 2016. 
http://www.bloomberg.com/news/articles/2006-04-11/jeb-bushs-big-biotech-push 
8 "The 2015 Florida Statutes." Online Sunshine. Florida Legislature. Web. 2 Mar. 2016. 
http://www.leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&Search_String=&URL=0200-
0299/0288/Sections/0288.1089.html 
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15% of their royalties back into the state. Research and development (R&D) projects must 
furthermore: 
 
 Serve as a catalyst for an emerging or evolving technology cluster; 
 Demonstrate a plan for significant higher education collaboration; 
 Provide the state a break-even economic benefit within 20 years; and 
 Receive a one-to-one match from the local community. 
 
With the exception of a 2013 agreement with an aircraft manufacturing firm, the 
program has primarily targeted biotech R&D businesses. According to data obtained from 
the DEO’s Economic Development Portal, nine firms have been paid $359.1 million 
through the IIP to date (not including the $310 million paid to Scripps). A March 2015 
article by Reuters estimated that state funding for IIP businesses and Scripps, combined 
with matching funds at the local level, have totaled over $1.32 billion. Table 2 contains a 
description of funds contracted to IIP recipients and to Scripps. 
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Table 2: State Funds Contracted and Awarded to Innovative Businesses 
 
Source: Department of Economic Opportunity’s Economic Development Portal 
 
SEEDING A CLUSTER AT LAKE NONA 
Such a combination of public and private efforts provided the foundation for the 
development of Medical City at Lake Nona. A combination of state-level incentives under 
Governor Jeb Bush, local-level incentives provided by the Orlando community and the 
University of Central Florida, and private support from the Tavistock Group attracted a 
range of health and science firms to Lake Nona.  
A study conducted by the Milken Institute in 2006 found that Orlando “possesses 
several of the attributes essential for the formation of a successful life-science industry” 
and that there was thus a “strong reason to believe that a life-science cluster could thrive 
in the Orlando region”.9 A strong hospital system, UCF’s preexisting research strengths 
and technology commercialization efforts, community support, and adequate local physical 
infrastructure were among these essential attributes. 
                                                 
9 Quintero, Fernando. "Burnham's Impact May Rival Disney's in Metro Orlando."Orlando Sentinel. Web. 3 
Mar. 2016. <http://www.orlandosentinel.com/features/orl-burnham-overview-100409-story.html>. 
Scripps 
Research 
Institute
Sanford  
Burnham 
Medical 
Research 
Institute
Torrey Pines 
Institute for 
Molecular 
Studies
SRI 
International
Hussman 
institute for 
Human 
Genomics
Max Planck 
Florida 
Corporation
Vaccine 
Gene 
Therapy 
Institute
Charles Stark 
Draper 
Laboratory, Inc.
IRX 
Therapeutics, 
Inc.
County Palm Beach Orange St. Lucie Pinellas Miami-Dade Palm Beach St. Lucie Hillsborough Pinellas
IIP Recipient No Yes Yes Yes Yes Yes Yes Yes Yes
Date of Award 2003 10/30/2006 11/16/2006 11/22/2006 1/9/2008 3/12/2008 4/17/2008 6/30/2008 10/28/2011
Funding 
Agreement Term
N/A 20 years 20 years 20 years 12 years 20 years 20 years 20 years 20 years
Jobs Committed N/A 303 by 2016 189 by 2015 200 by 2016 296 by 2016 135 by 2018 200 by 2018 165 by 2015 283 by 2017
Jobs Confirmed 
To Date
Not 
Available
234 124 86 139 94 120 61 Not Available
ROI Committed N/A $1.63 $3.53 $5.51 $2.54 $3.86 $4.66 $5.25 $13.77 
Amount 
Contracted
$310,000,000 $155,272,000 $32,000,000 $20,000,000 $80,000,000 $94,090,000 $60,000,000 $15,000,000 $600,000 
Amount Received $310,000,000 $137,840,513 $27,772,000 $19,648,853 $59,200,000 $94,090,000 $60,000,000 $14,000,000 $600,000 
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The strength of the Orlando economy, combined with the array of financial 
incentives provided through the IIP, drew Sanford Burnham to Lake Nona. Sanford 
Burnham was among the first institutions to commit to locate to Medical City in 2006. As 
part of the Innovation Incentive Program, Sanford Burnham committed to delivering 303 
high-paying jobs within ten years and a return on investment of $1.63 for every dollar 
invested by the state at the end of 20 years.  
Expectations for Sanford Burnham’s impact on the local economy, however, far 
exceeded the commitments made through the IIP as it was seen as an anchor institution for 
the Orlando life science cluster.  Sanford Burnham’s reputation, pivotal role in the 
development of the San Diego biotech cluster, and collaborative research approach were 
expected to draw in other biotech firms. Some reports anticipated the institute would yield 
local economic impacts on par with that of Disney.10  
Indeed, a number of large partners located to Medical City soon after Sanford 
Burnham’s commitment, including a new VA Hospital, Nemours Children’s Hospital, 
M.D. Anderson (which has since relocated), the UCF College of Medicine, and a UF 
research facility. This constellation of life science firms attracted to Lake Nona would, in 
theory, form the foundation for the establishment of a biotech cluster in the Orlando region. 
Non-local experts saw potential in this policy-driven cluster development strategy; Duane 
Roth, CEO of CONNECT, a tech-business accelerator in San Diego, stated that "By 
convincing existing institutions like Burnham — which got its start here in San Diego — 
to expand to Orlando rather than trying to lure startups was nothing less than brilliant," 
Roth said. "That was a way to speed up the pace and not have to start from scratch."11 Lake 
Nona partners themselves referenced cluster-like benefits as key reasons for locating at 
                                                 
10 Ibid. 
11 Ibid. 
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Lake Nona; Sanford Burnham President and CEO John Reed stated that the chance to 
immediately be part of a cluster, “working in proximity to a diversity of partners,” was the 
single biggest factor in his organization’s decision to locate in Orlando. 
 
LACKLUSTER PERFORMANCE OF LAKE NONA 
Despite the promise and initial progress of the Lake Nona cluster, the cluster has 
not prospered as originally hoped. Several key partners have been slow to cement a 
presence in the area. The Burnett School of Biomedical Sciences, M.D. Anderson and 
Sanford Burnham were the first of the key Medical City partners to open in 2009, several 
years after their initial commitments.1 Because of ties with another hospital in Florida - 
which located downtown instead of in Medical City - MD Anderson has actually left the 
Lake Nona medical complex. The College of Medicine – the presence and anticipated 
success of which was critical for several partners’ decisions to locate at Lake Nona - did 
not open its building to until 2010 (see Chapter 6 for further details on the role and 
development of the UCF College of Medicine at Lake Nona).  Nemours Children’s 
Hospital and the UF Academic and Research Center did not open until late 2012, more 
than four years after their commitments. The huge VA hospital, which broke ground in 
2008 and was initially expected to be completed in 2012, still is not fully operational 
(although some services opened in 2015).12  
  Underscoring the slow development of the cluster is the lackluster total 
employment within the medical plaza. According to the Florida Department of Economic 
Opportunity’s Economic Development Incentive Portal, at the time this paper was written 
Sanford Burnham had only delivered 234 of the 303 professional positions promised by 
                                                 
12 "Orlando VA Hospital Opens Years Behind Schedule." Wesh.com. Wesh Orlando, 26 May 2015. Web. 5 
Mar. 2016. <http://www.wesh.com/health/dedication-planned-for-new-orlando-va-hospital/33202944>. 
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2016 as part of the Innovation Incentive Program (IIP). Other partners who established 
themselves much later at Lake Nona have also failed to deliver jobs as anticipated. 
 Furthermore, despite access to UF business incubators, not a single spinoff has been 
established based on research conducted by Lake Nona partners. This is important as 
spinoff companies are often considered a critical reflection of the success of an industrial 
cluster and the commercialization potential of basic research conducted by partners. 
 The struggles of Lake Nona, however, extend to other policy driven biotech efforts 
across the state. Critics have also noted the lackluster performance of other biotech firms 
which received large subsidies as part of Jeb Bush’s IIP, including Torrey Pines and 
Scripps. Joe Cortright, an expert in city planning, noted that even “after the establishment 
of Scripps, Sanford-Burnham, and Torrey Pines, Florida has not received a higher 
percentage of venture capital money than it did 15 years ago.”13 In a 2014 report by 
Florida’s Office of Economic and Demographic Research, the state of Florida itself 
acknowledged that the Innovation Incentive Fund “does not break even” when calculating 
economic returns.14 
 The lackluster development of the Lake Nona complex and key biotech firms 
supported under Jeb Bush’s biotech push is particularly important to understand given the 
large sums of money dedicated to promoting their development. According to Reuters, 
when matching funds contributed by cities and counties to attracting biotech firms is taken 
into consideration, Florida spend more than $1.3 billion. The remainder of this paper is 
dedicated to analyzing the actual performance of Lake Nona, exploring the reasons for its 
                                                 
13 Bauder, Dan. "Florida Biotech Subsidies Not Working." San Diego Reader. San Diego Reader, 8 July 
2015. Web. 4 Mar. 2016. <http://www.sandiegoreader.com/news/2015/jul/08/citylights1-florida-biotech-
subsidies-not-working/#>. 
14 Szep, Jason. "How Jeb Bush's Big Bet on Florida Economy May Come Back to Haunt Him." Reuters. 
Reuters, 2 Mar. 2015. Web. 4 Mar. 2016. <http://www.reuters.com/article/us-usa-election-bush-biotech-
insight-idUSKBN0LY0CH20150302>. 
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poor performance, and analyzing whether there is hope for the complex to meet 
expectations moving forward. 
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Chapter 3: Lessons Learned from Successful Biotech Clusters 
After clarifying the concept of an industrial cluster, this chapter provides a qualitative 
analysis of the historical development of successful biotech and life sciences clusters in the 
United States - including Philadelphia, Boston and San Diego. Lessons learned from the 
development of these clusters is then applied to the situation at Lake Nona. 
 
THE CONCEPT OF A CLUSTER 
Biotechnology firms tend to form close to each other and other businesses in the 
life science industries, forming a cluster.15 The concept of industrial clusters has its roots 
in the works of Alfred Marshall regarding the spatial concentration of firms,16 and became 
a subject of intense research following Michael Porter’s 1990 book titled The Competitive 
Advantage of Nations.17  In later works, Porter called a cluster “a geographically proximate 
group of interconnected companies and associated institutions in a particular field, linked 
by commonalities and complementarities”.18 A later definition of clusters by Morisini as 
“a socioeconomic entity characterized by a social community of people and a population 
of economic agents localized in close proximity in a specific geographic region” is also 
commonly referenced. In general, an industrial cluster can be understood as a group of 
similar and related firms in a defined geographic area that share common markets, 
technologies, and worker skill needs, often linked by buyer-seller relationships. 
                                                 
15 The Milken Institute defines the “life sciences” as encompassing six major industries: pharmaceuticals, 
biotechnology, life sciences R&D, medical devices, health-care services, and supporting industries. 
16 Marshall, Alfred, 1842-1924. Principles of Economics: an Introductory Volume. 8th ed. London: 
Macmillan and co., limited, 1936. 
17 Porter, Michael E., 1947-. The Competitive Advantage of Nations. New York: Free Press, 1990. 
18 Porter, Michael E. "Location, competition, and economic development: Local clusters in a global 
economy." Economic development quarterly 14.1 (2000): 15-34. 
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Clusters consist of companies, suppliers, and service providers, as well as 
government agencies and other institutions that provide specialized training and education, 
information, research and technical support.19 The geographic concentration of firms in a 
related industry drives industrial productivity and innovation by promoting both 
competition and cooperation between firms. Easy access to specialized knowledge, labor, 
infrastructure, suppliers and customers reduces transaction costs for firms and enhances 
productivity. Clusters also promote innovation by allowing firms to gain insight into 
consumer preferences, providing them the opportunity to collaborate with others within 
their industry and simply heightening peer pressure. 
Often an “anchor tenant” - usually a large established entity - fosters the 
development of a cluster. Universities frequently serve as anchor tenants for high tech 
industrial clusters like biotechnology and the life sciences more broadly. Strategic alliances 
with universities help firms access skilled labor, knowledge spillovers, complementary 
academic research and research facilities. The commercialization of publicly funded 
research also has substantial economic benefits for the local area. Hausman (2012) 
examines the extent to which universities stimulate nearby economic activity, finding that 
long-run employment and wages rise in industries related to a universities’ preexisting 
innovative strengths, and that these benefits increase with geographic proximity to the 
university.20 The power of local universities to engender economic growth has also been 
underscored by the work of Moretti (2004) who finds that university spillovers result in 
productivity gains for local industry, and Glaeser and Saiz (2004) who find that human 
capital is a strong predictor of both population and productivity growth in cities and 
                                                 
19 "Clusters 101." U.S. Cluster Mapping. Harvard Business School. Web. 1 Mar. 2016. 
20 Hausman, Naomi. "University innovation, local economic growth, and entrepreneurship." US Census 
Bureau Center for Economic Studies Paper No. CES-WP-12-10 (2012). 
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metropolitan areas.21  Zucker et. al. (1998) highlight the critical role human capital as 
embodied in star scientists - often located at universities - in promoting the development 
of the biotechnology industry in particular.22 
Not all areas with strong universities, however, have been able to develop high-tech 
clusters. The correlation between university research funding with patents and company 
start-ups is weak and not statistically significant.23 In some biotech clusters, government 
labs, other large companies, and research institutions have driven the development of 
biotech industry, suggesting that universities are helpful but not by themselves adequate 
for successfully incubating a biotech cluster. 
 
CASE STUDIES OF SUCCESSFUL BIOTECHNOLOGY CLUSTERS 
A brief analysis of the development of mature U.S. biotechnology clusters was 
undertaken in order to gain insight into the key opportunities and barriers that drove the 
development of each one. Philadelphia, Boston, and San Diego were chosen for analysis 
because they rank among the top 10 biotechnology clusters in the country. San Diego was 
of particular interest given the expectations that Sanford Burnham will apply lessons 
learned from the San Diego cluster development to catalyze the development of Medical 
City at Lake Nona. 
 
                                                 
21 Glaeser, Edward L., and Albert Saiz. The rise of the skilled city. No. w10191. National Bureau of 
Economic Research, 2003. 
22 Zucker, Lynne G., Michael R. Darby, and Marilynn B. Brewer. Intellectual capital and the birth of US 
biotechnology enterprises. No. w4653. National Bureau of Economic Research, 1994. 
23 Feldman, Maryann. "The locational dynamics of the US biotech industry: knowledge externalities and 
the anchor hypothesis." ATTI DEI CONVEGNI LINCEI-ACCADEMIA NAZIONALE DEI LINCEI 203 
(2004): 109. 
 18 
Philadelphia 
Philadelphia’s current strengths in biotechnology go back to its prominent role in 
colonial history. As a cultural, industrial and commercial city Philadelphia was a natural 
center for innovation and began building academic and medical research infrastructure in 
the mid-18th century. In 1751, Benjamin Franklin and Dr. Thomas Bond founded 
America’s first hospital, Pennsylvania Hospital, still a leading medical center. That same 
year, the University of Pennsylvania (also co-founded by Benjamin Franklin) held its first 
classes. By 1765 the University of Pennsylvania’s School of Medicine was founded as 
America’s first medical school. 
Between 1790 and 1800 Philadelphia was the temporary capital of the United 
States, during which time both its population and position as an important industrial center 
in the new country were strengthened. The Embargo of 1807 and War of 1812 curtailed 
trade opportunities with Britain, further stimulating local innovation and industry; given 
that Britain was the major supplier of medicine at the time, medicine and pharmaceuticals 
were among these burgeoning industries.24  Friends Hospital, America’s first psychiatric 
hospital, was founded in 1813. In 1821, the American pharmaceutical industry was first 
organized by apothecaries with the creation of America’s first college of pharmacy and 
pharmacists’ association, the Philadelphia College of Pharmacy. Graduates of the 
Philadelphia College went on to found several of the largest pharmaceuticals in the world, 
including Eli Lilly and Company and GlaxoSmithKline, further cementing Philadelphia’s 
position as a leader in the pharmaceutical industry. The American Pharmaceutical 
Association was founded in Philadelphia in 1852. 
                                                 
24 Feldman, Maryann, and Yda Schreuder. "Initial advantage: the origins of the geographic concentration 
of the pharmaceutical industry in the Mid-Atlantic region." Industrial and Corporate Change 5.3 (1996): 
839-862. 
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Healthcare research and practice grew alongside pharmaceuticals in the first half of 
the 19th century. Jefferson Medical College was founded in 1824, the American Medical 
Association in 1847, and the Medical College of Pennsylvania in 1851. 
The illnesses and injuries which accompanied the Civil War increased demand for 
Philadelphia’s medical expertise. As one of the largest cities in the North and with existing 
strengths in medical research and pharmaceuticals, Philadelphia played a major role in 
receiving and treating the war’s wounded. The 1860s saw the creation of a number of 
numerous medical and sciences establishments. The Wyeth, one of the largest 
pharmaceutical companies prior to its acquisition by Pfizer in 2009 – was founded in 1860. 
The momentum from the Civil War carried the development of the medical industry in 
Philadelphia through the last half of the 18th century, during which time Philadelphia 
Orthopedic Hospital, Johnson and Johnson, Merck Pharmaceuticals, and Wistar Institute 
(America’s first independent biomedical research institute) were founded. 
Philadelphia’s medical expertise rested and built upon the foundations laid prior to 
the 20th century and provided a natural segue into its involvement in biotechnology. 
Centrocor, Philadelphia’s first biotechnology company, was co-founded by the former 
director of the Wistar Institute. The founding of Cephalon in 1987 is considered the next 
key stepping stone in Philadelphia’s development into a biomedical hub. Human capital, 
innovations and funding provided by strong pharmaceutical firms and universities 
encourage firms to locate in Philadelphia. However, Philadelphia remains relatively 
stronger in biomedical research than in commercialization.25 
To summarize, the Philadelphia’s strengths in medical research and 
pharmaceuticals are not due to any natural advantage (such as location near raw materials) 
                                                 
25 Cortright, Joseph, and Heike Mayer. Signs of life: The growth of biotechnology centers in the US. Center 
on Urban and Metropolitan Policy, The Brookings Institution, 2002. 
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but historical circumstance.26 A number of research, academic and professional 
organization founded during the colonial, revolutionary and industrial history of the city 
are still in existence today as leaders in their fields. This organizational and research 
strength enabled, in turn, enabled the growth of biotechnology industry in the area 
beginning in the late 1970s. The biotechnology industry, however, did not grow rapidly– 
eight full years existed between the establishment of the city’s most frequently noted 
biotechnology firms. Although Philadelphia has maintained is reputation as a key player in 
the life sciences, it has struggled to translate its research strengths to commercialization on 
a scale that competes with other top life science and biotechnology clusters.27 
 
Boston 
Boston’s current position as a leader in the life sciences is inextricably linked with 
the area’s leading research and academic institutions. Harvard University, the nation’s 
oldest institution of higher learning, was established in the Boston area in 1636, and its 
affiliated medical school was founded in 1782. The Massachusetts College of Pharmacy 
and Health Sciences, Massachusetts Institute of Technology (MIT), Tufts University and 
Boston College were but a handful of the universities founded in the Boston area during 
the 19th century. These universities were early leaders in the life sciences; MIT, as a 
technology oriented institute, initially considered life sciences from an engineering 
perspective, and collaboration between MIT and Harvard helped to found the Harvard 
School of Public Health in 1913.28  
                                                 
26 Feldman, Maryann, and Yda Schreuder. "Initial advantage: the origins of the geographic concentration 
of the pharmaceutical industry in the Mid-Atlantic region." Industrial and Corporate Change 5.3 (1996): 
839-862. 
27 DeVol, Ross, et al. "The Greater Philadelphia Life Sciences Cluster." The Milken Institute (2005). 
28 Sharp, Phillip. "Life Sciences at MIT: A History and Perspective." MIT Faculty Newsletter XVIII.3 
(2006). MIT. MIT. Web. 4 Mar. 2016. <http://web.mit.edu/fnl/volume/183/sharp.html>. 
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Leadership in the biomedical sphere is reflected in the receipt of numerous Nobel 
prizes even prior to the birth of biotechnology; Salvador Luria, David Baltimore and Baruj 
Benacerraf won Nobel Prizes in Physiology or Medicine in 1969, 1975 and 1980 
respectively, and Walter Gilbert’s work on the structure of DNA earned him the Nobel 
Prize in Chemistry in 1980. These star scientists attracted high levels of research funding; 
a 2009 study by the Milken Institute ranked Boston first among MSAs for life sciences 
R&D funding.29   
Beyond providing human capital and research funding critical to life sciences and 
the niche biotechnology industry in particular, Boston area academic institutions were 
pioneers in the establishment of technology transfer.30 MIT established an office for 
technology transfer as early as 1940, followed by Boston University and Medical Center 
in 1976, Harvard University in 1977 and Tufts University in 1978. This technology transfer 
infrastructure placed Boston universities in a unique position not only to support the 
biotechnology industry with basic research but assist in translation and commercialization. 
The value of pharmaceutical-biotech research contracts, an indicator of commercially 
promising biotech research activities, grew rapidly between 1980 and 2000, exceeding the 
value of these alliances in all other major biotechnology centers.31 
Commercialization of life science and biotechnology discoveries was also 
supported by the strength of the venture capital system in Boston. Organized venture 
capital has its roots in efforts by New England leaders to strengthen the local and national 
economy by supporting small business; Boston figures were at the forefront of these 
                                                 
29 DeVol, Ross, et al. "The Greater Philadelphia Life Sciences Cluster." The Milken Institute (2005). 
30 Stevens, Ashley J. "The Biopharmaceutical Industry in Massachusetts-The Triple Helix in 
Action." Journal of Biolaw and Business 10.3 (2007): 33. 
31 Cortright, Joseph, and Heike Mayer. Signs of life: The growth of biotechnology centers in the US. Center 
on Urban and Metropolitan Policy, The Brookings Institution, 2002. 
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efforts.32 The former dean of Harvard Business School and president of MIT joined forces 
in 1946 to establish the American Research and Development Corporation, one of the first 
two venture capital firms in the country. 
Spinoffs from strong universities and medical centers, assisted by technology 
transfer programs and the access to venture capital, gave rise to a number of biotechnology 
companies beginning in the 1980s. Biogen, the first biotechnology company in 
Massachusetts, was founded in 1978 by researchers from Harvard and MIT. Genzyme, 
another early leader in the biotech industry, was established in 1981 based on research 
carried out at Tufts University. Commercialization activity gained momentum through the 
following decades; between 1980 and 2000 Boston had the largest concentration of 
biotechnology firms in the country, second only to San Francisco (the birthplace of 
biotechnology). Local government played an active role in encouraging the biotechnology 
cluster, establishing the Massachusetts Centers for Excellence Corporation (MCEC) and 
Massachusetts Biotechnology Council (MBC) to promote, organize and provide services 
to biotechnology companies. 
Biotechnology as an industry is unique in its reliance on basic research and venture 
capital funding. Given that both of these elements were established in the Boston area prior 
to the 1980s, Boston was a natural place for the industry to establish itself beginning in the 
1980’s. Although a number of pharmaceutical firms, biotech companies and financial 
institutions arose to support the industry, organizational theorists Powell and Padgett 
(2012) have shown that the cluster was primarily dependent upon the networks 
                                                 
32 Hsu, David H., and Martin Kenney. "Organizing venture capital: the rise and demise of American 
Research & Development Corporation, 1946–1973."Industrial and Corporate Change 14.4 (2005): 579-
616. 
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promulgated by research institutes through the late 1990s, and would have collapsed 
without them.33 
 
San Diego 
Although the Scripps Institution of Oceanography (SIO) established an early life 
science research presence in San Diego, the formation of several non-profit research 
institutes in the mid-20th century formed the foundation for San Diego’s eventual 
recognition as a life science industry cluster. The Scripps Research Institute (Scripps) was 
founded in 1955 with a focus on education and research in the biomedical sciences and 
today remains a leading life science research body in the nation. In 1960, Jonas Salk 
established the Salk Institute for Biological Studies in San Diego after the city donated land 
(which had previously been zoned by the city for research purposes) for its establishment. 
Several prominent bio-scientists including Francis Crick, known for his co-discovery of 
DNA, contributed to research efforts of the Salk Institute.  
The area lacked a supporting academic research anchor until 1960, when the 
University of California at San Diego was established through state appropriations, a 
donation from the defense company General Dynamics and a gift of 63 acres from the city 
of San Diego in the Torrey Pines area close to SIO, Scripps and the Salk Institute.34 In 1976 
the Torrey Pines research zone gained another prominent tenant with the establishment of 
the La Jolla Cancer Research Center (now Sanford Burnham Prebys Medical Discovery 
Institute). 
                                                 
33 Padgett, John F., and Walter W. Powell. The emergence of organizations and markets. Princeton 
University Press, 2012. 
34 "Campus Timeline." UC San Diego. Web. 10 Mar. 2016. <http://ucsd.edu/timeline/>. 
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In addition to non-profit research institutes focused on the biomedical research, the 
military played an important role in building San Diego’s research presence. A naval 
laboratory and federal R&D support built a research community focused on defense and 
attracted talented engineers and scientists. Research-oriented defense companies, including 
General Atomics (which supported the establishment of UCSD), flocked to the area. 
Collaboration with the military and these defense companies contributed to the rise of high-
technology industries in San Diego. Following the end of the Cold War, the demand for 
defense-related work fell and idle talent formerly linked to the military sector provided a 
vital labor pool for the life science and biotechnology industries. 
Although San Francisco took the lead in the early development of the 
biotechnology industry, San Diego was home to Hybritech, one of the earliest dedicated 
biotech firms in the country, founded in 1978 by former Stanford researchers. In 1985 the 
business accelerator CONNECT was founded in response to the continued growth of high-
tech industry in the area with the goal of promoting high-tech businesses by linking 
entrepreneurs to public research efforts and business support services (including 
financing).  
The continued success of Hybritech led to its acquisition in 1986 by the 
pharmaceutical company Eli Lilly. Although Hybritech eventually disappeared under Eli 
Lilly’s leadership, former scientists and leaders at Hybritech went on to found numerous 
spinoff companies and several VC firms in the San Diego area throughout the 1980s and 
1990s. Twenty-five years after Hybritech’s founding, more than 50 firms could trace their 
establishment back to Hybritech.35 The efforts of ex-Hybritech played a key role in the 
establishment of the biotechnology industry in San Diego. 
                                                 
35 DeVol, Ross, et al. "America’s Biotech and Life Science Clusters." San Diego’s Position and Economic 
Contributions. Santa Monica: Milken Institute(2004). 
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To summarize, San Diego’s current position as a leading life science cluster traces 
back to presence of strong research anchor institutions. Talent, complementary research 
and collaboration with the defense industry strengthened basic research strengths which 
would ultimately support the development of the biotech industry. The unique story of 
Hybritech and its spinoffs was also an unplanned turn of events which strengthened the 
industrial cluster. 
 
CONCLUSION 
This slow historical development of existing biotech clusters should temper 
expectations of rapid establishment and growth of new ones. The very nature of the life 
science and biotech industry constrains the growth rate of clusters. Biotech R&D, for 
instance, is a long, complex and expensive process. Several years may be spent in the basic 
and preclinical research stages leading to drug discovery, and the average time needed to 
achieve FDA approval following drug discovery exceeds 10 years. Only 12% of medicines 
that enter clinical trials are ultimately approved by the FDA, and the average cost to 
develop one new drug exceeds $2.6 billion.  Thus, even with adequate access to capital, 
skilled labor, and strong partnerships, biotech clusters should grow gradually. 
The case studies presented indicate that there is no single recipe for industrial 
cluster development. Pharmaceutical companies, for instance, provided an anchor for the 
development of biotechnology in Philadelphia, while universities and independent research 
institutes anchored the industry in Boston and San Diego respectively. The presence of 
these anchors and development of the life science industry more broadly had traced to 
developments from several decades (in some cases centuries) prior, indicating a path-
dependence in cluster development.  
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However, the recent study and codification by academics and practitioners of the 
economic development of clusters established in the 20th century may allow aspiring 
clusters in places like Orlando to fast-forward their development. In addition, the clusters 
analyzed in this section grew throughout the 1980s and 1990s. Policy driven clusters such 
as Lake Nona have modern benefits of faster and more efficient communication with 
partners. Better communication, when combined with more efficient travel methods 
compared to the 20th century, should increase opportunities for collaboration with other 
partners and facilitate cluster development. Increased mobility of star scientists should also 
facilitate cluster development. Florida has a particular advantage in attracting companies 
and researchers given the low cost of living relative to successful biotech clusters like San 
Diego, Boston and Philadelphia. 
Although the communication and transportation benefits of the 20th century, the 
relative economic attractiveness of the state of Florida, and the support of local policy 
makers is likely to facilitate the development of the cluster at Lake Nona, it would be 
unrealistic to expect a successful cluster to develop overnight. Major clusters have taken 
decades to develop in the past, and the lack of consideration of the path-dependent nature 
of cluster development may have produced unrealistic expectations by policy makers 
regarding the pace of development of the cluster at Lake Nona. 
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Chapter 4: Venture Capital and the Biotech Industry 
This chapter assesses the role of venture capital in supporting the biotech industry, and 
analyzes how trends in venture capital funding in the past decade may have hindered or 
supported the development of an industrial cluster at Lake Nona. After clarifying the 
importance of venture capital for biotech firms, national trends in venture capital funding 
for the life science and biotech industry are analyzed, and the relevance of these trends for  
Lake Nona are discussed.  
 
FUNDING FOR BIOTECH STARTUPS 
Funding Requirements 
Biotechnology is generally viewed as a high-risk industry due to the need for large 
front-end investments and high rates of attrition throughout a lengthy R&D and FDA 
approval process. A 2014 study by the Tufts Center for the Study of Drug Development 
estimated that the average cost needed of gaining FDA approval for a new drug rose by 
more than 145% within a decade - from $1 billion in 2003 to $2.6 billion in 2013.36 This 
figure includes $1.395 billion in out-of-pocket costs and $1.16 billion in opportunity costs. 
Although Tuft’s methods and final number are controversial, the out-of-pocket and total 
costs are frequently cited by pharmaceutical and biotechnology companies to justify high 
drug prices and the need for substantial funds from investors. 
The out-of-pocket expenditures related to drug development are particularly 
burdensome for young biotech firms given their inability to support R&D efforts with 
revenue from other products. The 2015 BDO Biotech Briefing examined 10-K SEC filings 
                                                 
36 Peters, Sandra. "Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion." Tufts 
Center for the Study of Drug Development. Tufts University, 18 Nov. 2014. Web. 15 Mar. 2016. 
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of publicly traded companies listed on the NASDAQ Biotechnology Index and found that 
the average annual R&D expenditures of biotechnology firms increased by 18% to $55.6 
million. Average revenues increased by 44% during the same period. Large biotech 
companies (over $50 million in revenue), however, witnessed the majority of this revenue 
growth, with an average revenue increase of 52% compared to 7% for small firms. R&D 
as a percentage of revenues for small biotech firms in 2014 rose from 261% in 2013 to 
313% in 2014, but fell from 101% to 83% for large firms. 
In addition to the high R&D costs associated with drug development, biotech 
investors must weigh risks associated with a decade-long investment horizon. The total 
average length of time needed for an experimental drug to navigate the FDA approval 
process is ten years.37 On average, only five of every 5,000 (0.1%) of drugs are selected 
for clinical trials, and, of those selected, only 12% will ultimately receive FDA approval.38 
In stark terms, only 0.012% of identified drugs will receive FDA approval and move on to 
the marketing stage.  FDA approval, however, does not in and of itself guarantee that 
investors will recover their investment. Only two of every ten drugs that enter the 
commercialization stage of the innovation pipeline will return revenues that match or 
exceed R&D costs.39 
 
                                                 
37 2015 Profile: Biopharmaceutical Research Industry. Washington, DC: Pharmaceutical Research and 
Manufacturers of America, 2015.Web. 
<http://www.phrma.org/sites/default/files/pdf/2015_phrma_profile.pdf> 
38 "The Beginnings: Laboratory and Animal Studies." U.S. Food and Drug Administration, 27 Apr. 2015. 
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Funding Sources 
Clearly, the growth of a new biotechnology firm depends heavily on its ability to 
access large and long-term investments.  However, highly variable returns, a lack of 
collateral, and information asymmetries between firms and potential investors often limit 
biotechnology firms’ access to traditional debt financing.40  These same limitations 
constrain both young and more established (i.e. publicly traded) biotechnology firms.  In 
2014, for example only 34% of publicly traded biotechnology firms sought debt 
financing.41 Biotechnology startups must therefore turn to a variety of grants and equity-
based financing options to help launch and expand their operations, including: 
 
 Grant funding.  A variety of grants are available for biotechnology firms at the 
federal, state and local government levels as well as from private healthcare 
foundations. Unlike equity-based financing, grant funding does not demand a return 
on investment. Grant funding, however, is often limited and targeted at the earliest 
stages of product development. The Small Business Innovative Research (SBIR) 
program, for example, one of the most popular funding sources for small biotech 
firms, coordinates federal grants of less than $1 million only for pre-
commercialization development objectives. 
 Angel funding. High net worth and well-connected individuals with an interest in 
the biotechnology industry are another source of financing for biotechnology 
companies. Angel investors typically provide seed funds of less than $250,000 for 
early stages of development. In 2014 angels invested over $1.65 billion in 870 
                                                 
40 Carpenter, Robert E., and Bruce C. Petersen. "Capital market imperfections, high‐tech investment, and 
new equity financing." The Economic Journal112.477 (2002): F54-F72. 
41 2015 BDO Biotech Briefing.. BDO USA, 2015.Web. <https://www.bdo.com/getattachment/8d9c5a19-
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deals, 18% of which were in the healthcare and life sciences sector.42 Although 
angel investors seek a high return on their investments, they often demand less 
involvement in company politics and operations than traditional venture capital 
firms. 
 Large corporations. In an increasingly competitive environment, large 
pharmaceutical companies are outsourcing R&D activities by investing in the 
innovative research efforts of biotechnology companies in exchange for rights to 
drugs developed. The majority of pharma-biotech deals are struck during or after 
the clinical development stage.43 Licensing and collaboration with pharmaceutical 
companies provides biotechnology not only with financial resources to support 
development efforts but manufacturing and marketing expertise for the successful 
commercialization of a product.  
 Venture capital. Venture capital has long been a primary source of funding for 
biotechnology firms. According the PricewaterhouseCoopers data, more than $7.4 
billion in venture capital funds were invested in U.S. biotechnology firms in 2015. 
Venture capital investments are significantly larger than funds obtained through 
grants and angel investors. In exchange, VC firms receive an equity or ownership 
stake and actively invest time an energy into steering the development of the firm 
and ensuring its success. Traditionally, venture capital is provided in later stages of 
development when products have displayed some potential for commercial success.  
 
                                                 
42 "2015 Halo Report." Angel Resource Institute. Williamette University, n.d. Web. 29 Mar. 2016. 
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Although biotechnology firms have access to a range of financing options, the scale 
of venture capital investments is unmatched by other funding sources.  The role of venture 
capital firms often goes far beyond that of a traditional financial intermediary, and VC 
firms may serve as an importance source of management expertise for new biotech firms. 
VCs often require an active role in the target firm’s board in order to influence strategy and 
governance.  Among other things, VCs may lend their business expertise to young firms 
by helping them to develop or refine business and financial plans, develop marketing 
strategies, and develop contingency plans in the event of failure. This business acumen 
may be particularly valuable for biotechnology spin-offs, many of which are founded by 
academics and scientists without a strong business background.  Venture capital, therefore, 
remains a unique and critical funding source for biotechnology startups. 
 
NATIONAL TRENDS IN BIOTECHNOLOGY VENTURE CAPITAL 
Following the burst of a “genomics bubble” which paralleled the dot com bubble 
of 2000, a recovering biotech industry experienced an upward trend in venture capital 
investment through 2007.  In 2008, however, as a result of the financial crisis, venture 
capitalists and private equity groups scaled back their investments across all industries, 
including biotechnology. Venture capital investment in the biotech industry continued to 
fall throughout 2010 as venture capitalists limited their investments and turned their 
attention towards less risky industries.  
Investment in the biotech industry began to recover in 2011, thanks in part to a 
strong public offering market for biotech firms, and in 2015 venture investment exceeded 
pre-recession levels. According to the fourth quarter life sciences MoneyTree Report from 
PricewaterhouseCoopers (PWC), 2015 venture capital funding for biotechnology (and the 
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life science industry more broadly) was the highest since the start of the MoneyTree data 
series in 1995. Venture capitalists invested more than $7.4 billion in 475 biotechnology 
deals in 2015, a 16.8% increase in value over 2014. As seen in Figure 2, this investment 
level was record-setting levels in both nominal and real (inflation-adjusted) terms. 
 
Figure 2: Annual VC Investment in the U.S. Biotech Industry (constant 2009 $) 
 
It is important to note, however, that the total number of deals in the industry has 
remained relatively flat since the recession, implying that surging investment levels are the 
result of larger rather than more numerous investments. Start-up and early stage companies 
may find it particularly challenging to secure venture capital funding in such an 
environment. 
The stagnant number of total deals in the industry is particularly concerning for 
biotech start-ups in light of declining first-time funding. As seen in Figure 3, first-time 
funding for biotech companies has fallen since the late 1990s, both as a percentage of total 
dollars invested and of the total number of deals, indicating that venture capital firms are 
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increasingly focusing their investments on more established biotech firms which have been 
previously vetted for venture capital funds. Although first-time funding spiked in 2015, it 
remains to be seen whether this trend will continue in the future. 
 
Figure 3: First Sequence Biotech Investments as a % of Total Biotech Investments 
 
A look at PWC’s venture capital funding data by stage of company development 
provides a more nuanced view of venture firm’s investment preferences. PWC classifies 
companies receiving venture capital as being in either the seed, early, expansion or late 
stages of development. Because PWC does not provide industry-specific definitions of 
company development stages, an accurate cross-walk between company development 
stage (as defined by PWC) and a biotech company’s general location along the more 
industry-specific innovation pipeline cannot be established. In general, however, life 
science investors consider products in the preclinical testing stage to be early-stage 
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investments, while companies whose products have been selected for the clinical stage or 
are already being marketed are considered in the later stages of development.44,45 
As seen in Figure 4, seed stage venture investments in biotech have fallen steadily 
as a percentage of total deals since the Great Recession. In 2009, 122 seed stage 
investments worth $713.6 billion were made, compared with only 52 investments worth 
$452.9 billion (inflation-adjusted dollars) in 2015 – a decline of nearly 37% in value and 
57% in volume. 
 
Figure 4: VC Deals by Stage of Company Development 
 
Clearly, investor preference for the most nascent of biotechnology companies has 
waned. Investor interest in more established biotech firms has also fallen.  The share of 
investments made in companies in the expansion and later stages of development has 
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45 Seed funding will be understood to be particularly valuable to new biotechnology startups, as funding 
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shrunk slowly as a percentage of total deals over the last decade, falling from 59% of all 
deals in 2004 to 31% of all deals in 2015. Instead, investor interest and resources since the 
Great Recession have shifted towards early-stage biotechnology companies. In 2015 58% 
of all biotechnology venture investments flowed towards early-stage companies compared 
to 32% in 2009. 
In sum, while the average venture investment made in the biotech industry has risen 
dramatically in the past few years, the total number of investments has remained flat. This 
stagnation, combined with falling first-time funding within the industry, implies that 
investors are sticking with biotechnology firms in which they have previously invested. 
These follow-up funds seem to be directed at early stage firms which have likely not yet 
reached the commercialization stage of the innovation pipeline or begun to see significant 
revenue growth.  Companies in the earliest stages of development (i.e. seed) are a falling 
priority for investors. In this environment, new biotech start-ups may find it difficult to 
gain traction by securing venture funding. 
 
IMPLICATIONS FOR LAKE NONA 
As venture capital firms lowered the risk-level of their biotech portfolios after the 
Great Recession by decreasing seed stage and first-time venture funding, post-recession 
startups would have relied more heavily than normal on alternative early funding sources.  
However, the Great Recession also impacted funding available from other early stage 
investors. Funding provided through NIH grants, for example, plunged during the Great 
Recession and has only begun to rebound in the last year or two. 
Given the large up-front costs of biotech R&D research, such constraints on early 
stage funding may have naturally limited the ability of collaboration at Lake Nona to yield 
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spin-off companies. Rebounding public funding will play an important role in supporting 
innovative discovery research at Lake Nona which may ultimately result in applied 
research at a spin-off company. However, in light of venture firms’ preference for funding 
more established biotech startups which have moved beyond the seed stage of 
development, policy makers have an important role to play in ensuring companies have 
funding available to help them move from basic to preclinical research. 
At the federal level, the funding for Phases I and II of the SBIR should be increased 
to ensure increased funding for basic research. NIH funding, which has fallen in real terms 
every year for the past decade, should be increased for similar reasons (see Chapter 5 for a 
more in depth discussion regarding NIH funding and relevance for Lake Nona). Other 
researchers have suggested that the FDA create a unique testing route for biomedical and 
pharmaceutical compounds which would allow for earlier demonstration of product 
efficacy to attract funding earlier.  
States may also play a role in promoting greater and earlier venture capital 
investments. The State of New York, for instance, has led the development of a unique 
venture capital funding pool by contributing state funds alongside pharmaceutical 
companies and venture capitalists. The collaborative venture capital pool may have the 
added benefits of overcoming local investment preferences of VC firms and encouraging 
corporate venture capital investment (a growing trend within the VC industry). 
Overall however, despite efforts by policymakers, Florida has remained a minor 
player in the venture capital scene and has failed to increase its relative proportion of 
national venture capital funds. The influence of the Great Recession on venture capital 
made it even more difficult for Florida biotech firms to secure VC funding. Barring 
dramatic shifts in the risk-tolerance of the venture capital industry, aspiring clusters like 
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Lake Nona will continue to face a challenge in attracting adequate venture capital in order 
to fuel the commercialization of biomedical discoveries. 
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Chapter 5: NIH Funding 
In recognition of the importance of NIH funding in fueling basic research efforts of 
a biotechnology cluster, this chapter analyzes trends in NIH funding over the past decade 
and the implications of these trends for the development of the Lake Nona cluster. 
 
AN UNTIMELY CRISIS 
The National Institute of Health is the largest single source of support for 
biomedical research in the United States, accounting for four-fifths of U.S funding for 
federally funded life sciences research. NIH funding is typically provided in the form of 
grants to scientists working at universities and institutions. NIH funding (and federal 
funding more generally) are particularly critical for the basic research stage of the 
biomedical and life science innovation pipeline, as private funders such as angel investors 
and venture capitalists typically provide financial support once a product or business idea 
has materialized and a return on their investment can be foreseen. 
In 1998, Speaker of the House Newt Gingrich and President Bill Clinton secured 
bipartisan support to substantially increase federal spending in biomedical research.46 
Political and popular support of biomedical and life science research stemmed from a 
number of scientific developments in the area (including cancer treatment) as well as a 
strong economy and healthy debt levels. Funding for biomedical and life science research 
continued to rise over the next decade and, in 2005, at the time that key partners were 
committing to Lake Nona and the biomedical cluster was beginning to take shape, NIH 
funding for biomedical research was close to an all-time high.  
                                                 
46 Pear, Robert. "Government Ready to Boost Spending for Biomedicine." The New York Times [New 
York, New York] 3 Jan. 1998: n. pag. The New York Times. Web. 20 Mar. 2016. 
<http://partners.nytimes.com/library/politics/010398clinton-budget.html>. 
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Much of the excitement surrounding Lake Nona would have rested on the promise 
of federal funding for cluster partners who would be engaged in basic research, including 
UCF and Sanford Burnham. Indeed, the Sanford Burnham Institute as a whole consistently 
ranks among the top four institutes with respect for NIH funding and it would have been 
reasonable to expect that they would continue to attract funding for their work in Orlando. 
In sum, the rapid development of the cluster at Lake Nona rested heavily on basic research 
funding from the NIH to support the research efforts of star scientists and their subsequent 
efforts to commercialize their discoveries through research. 
Unfortunately, the leaders of Lake Nona could not have foreseen the beginning of 
the financial crisis or the Great Depression, which had a devastating impact on NIH 
funding. As shown in Figure 5, annual NIH funding has declined consistently since 2005. 
Funding levels in 2015 were approximately 20% below peak funding levels in 2005 (this 
graph excludes funding from the temporary American Reinvestment and Recovery Act). 
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Figure 5: Annual NIH Funding (constant 2009 $) 
 
It may be argued that the simple difference in real funding, however, does not 
reflect the full impact of the fall in funding for Lake Nona scientists had partners expected 
NIH funding trends to continue. A better comparison might be actual funding against 
funding levels which might reasonably have been expected by Lake Nona founders in 
2005. The trend line incorporated in Figure 5 reflects funding levels Lake Nona partners 
and leaders could reasonably have expected had funding continued to increase according 
to historical trends. As can be seen in the graph, actual funding in 2015 (approximately $20 
billion) was nearly 85% lower than would have been anticipated by historical trends. Such 
a downturn in NIH funding would have slowed the progress of Lake Nona partners in 
meeting employment and research goals initially drafted at the height of basic research 
funding in 2005. 
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FUTURE PROSPECTS FOR NIH FUNDING 
Because of the importance of NIH funding in fueling basic research at Lake Nona, 
it is important to consider future funding prospects. Importantly, Congressional support for 
NIH funding seems to be returning. In 2016 Congress approved a $2 billion increase in 
NIH funding to $32.1 billion, effectively halting a decade long decline in funding. This 
support represented an increase of 6.6% over 2015 funding levels and was the largest 
increase in funding that the NIH has received from Congress since 2002.47 This funding 
increase exceeded the President’s request of a $1 billion increase in funding for the agency, 
underscoring that biomedical research has returned as a priority for policymakers and the 
public more broadly. 
In order to gain a better understanding of the future prospects for funding in the 
biotech sector, I interviewed Dr. David Denslow.  Dr. Denslow is a retired researcher from 
the Department of Business Economics at the University of Florida, and has a focus on and 
expertise in economic development within North Central Florida. In Dr.Denslow’s 
opinion, there are several reasons for optimism regarding the future of biotech, including: 
 
 Advances in technology. Unprecedented progress and discoveries in the life 
sciences is likely to pique the interest and support of the public and policymakers. 
Advances in research technology range have forwarded the development of 
personalized medicine and raised the promise of improved quality of life. Recent 
advances in Alzheimer’s research, for instance, may have played a role in the $350 
million increase in funding for research of the disease as part of the recent NIH 
funding increase. 
                                                 
47 Mervis, Jeffrey. "Updated: Budget Agreement Boosts U.S. Science." Science Mag. N.p., 18 Dec. 2015. 
Web. 20 Mar. 2016. <http://www.sciencemag.org/news/2015/12/updated-budget-agreement-boosts-us-
science>. 
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 Research spillovers. Dr. Denslow cited a recent economic study which 
demonstrated that nearly half of the patents resulting from NIH funding for a 
particular disease were associated with other diseases. The same study also showed 
that public R&D funding may actually increase rather than decrease private R&D 
funding.48 
 Demographics. As the aging baby boomer generation raises the average age of the 
U.S. population, the value of good health to the public rises and spending on life 
sciences should rise proportionally. As the population ages, federal spending on 
health care programs and research is likely to rise proportionally. The 
Congressional Budget Office (CBO), for example, has estimated that annual 
spending on major health care programs is likely to double in the next decade, rising 
from $936 billion in 2015 to $1,835 billion in 2026. 
 
CONCLUSION 
This chapter analyzed trends in NIH funding given the importance of federal 
funding for basic biomedical and life science research. Partners at Lake Nona would have 
relied heavily on this funding source, and successful basic research ultimately would have 
formed the basis for the formation of spinoff companies.  
At the time Lake Nona was formed, federal funding for the life sciences was at an 
all-time high. However, funding plummeted following the Great Recession. This 
unexpected fall would have directly limited the basic research efforts of key Lake Nona 
partners, effectively constraining the growth of the cluster and preventing them from 
achieving research and employment goals formed on the basis of trends through 2005. 
                                                 
48 Hunter, Philip. "More is less." EMBO reports 8.7 (2007): 626-628. 
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A recent rebound in funding and interest for the life sciences, however, may be a 
game changer for Lake Nona. Although this rebounding interest is recent, macro trends 
including an aging population and advances in technology are likely to sustain support for 
the biotech industry and the prospects for the successful formation of a biotech cluster at 
Lake Nona. 
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Chapter 6: The UCF College of Medicine 
The UCF College of Medicine was established in 2009 and was considered an anchor 
institution critical to the development of the Lake Nona cluster. Indeed, a 2006 study by 
the Milken Institute – often cited by Lake Nona supporters and visionaries – centered its 
economic impact estimates of the envisioned cluster around the College of Medicine. This 
chapter analyzes the successes and challenges of the new college in assessing whether the 
college has succeeded in catalyzing the development of Lake Nona as anticipated. 
  
CONTRIBUTION OF MEDICAL SCHOOLS TO LIFE SCIENCES CLUSTERS 
Universities often serve as anchors for research-intensive industry clusters; 
collaboration with university-based scientists allows partners to access research funding 
and core facilities, while a steady stream of university graduates provides access to a pool 
of highly skilled labor. Given that life science research is complemented by innovations 
across disciplines, firms in the life science and biotech industry benefit from proximity to 
a range of university departments.  Research-based colleges of medicine, however, play a 
particularly important role in fostering the development of life science clusters by 
providing access to infrastructure, funding and human capital unique to the biomedical 
sciences. 
 
Physical Infrastructure 
Among other things, a college of medicine provides access to specialized research 
facilities, equipment (e.g. wet laboratory space) and technicians. State-of-the-art university 
facilities help to attract and retain successful “star scientists” who, in turn, compete for 
federal grants and other research funding. Institutions with more research space are able to 
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hire more investigators and thus produce more research. Given that the number of NIH 
grantees, total federal grant funding and other metrics of research volume are often used in 
ranking systems, the expansion of research facilities may correlate directly with an 
institution’s ability to move up within ranking hierarchies. 
University research facilities also serve as a resource for research partners and 
private firms in the surrounding region.  In their annual reports on life sciences industry 
clusters, Jones Lang LaSalle (JLL) uses laboratory space as a key factor in assessing the 
promise and relative strength of life science clusters throughout the world. Although trends 
within the industry are increasing demand for specialized lab space and driving up rent 
prices in major clusters, life science firms remain entrenched in traditional geographic 
clusters given their need for R&D infrastructure and specific labor pools.49 However, JLL 
predicts that in the medium to long term these rising rent prices could push large life science 
firms to seek secondary markets outside of traditional large clusters. Ensuring that 
laboratory and incubator space is available at Lake Nona within College of Medicine 
facilities and the Guidewell Innovation Center will place Orlando within the consideration 
set of firms making such a move. 
 
R&D Funding 
A university’s ability to attract R&D funding is widely considered a measure of its 
academic strength; strong R&D infrastructure attracts “star-scientists” who enhance not 
only the research volume but research quality of a university.  The overall level of R&D 
expenditures institutions within a region can be viewed as an indicator of a region’s ability 
to innovate, encouraging both academic and non-academic funding recipients to undertake 
                                                 
49 Life Sciences Outlook. Rep. Jones Lang LaSalle, n.d. Web. 25 Mar. 2016. <http://www.us.jll.com/united-
states/en-us/Documents/Life-Sciences/JLL-US-Life-Science-Outlook-2015.pdf>. 
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and commercialize innovative research.50 Strong R&D infrastructure is critical to any 
region seeking to strengthen a life science industry. 
Colleges of medicine attract R&D funding to a region. A 2006 study by the Milken 
Institute found that the median annual R&D expenditures of universities with associated 
medical schools were nearly three times those of universities without medical schools - 
$224.8 million compared to $75.3 million.51 Furthermore, the median annual R&D 
expenditures by universities with medical schools located in life science clusters – such as 
San Diego, Raleigh-Durham, San Francisco and Philadelphia – was nearly $100 million 
more than by universities with medical schools not located in clusters.  
 
Human Capital 
A research-based college of medicine attracts human capital critical to the life 
science industry.52 Star scientists (as measured by research output) play a separate and even 
greater role than well-ranked universities in fostering the development of biotech industry 
clusters. As mentioned above, these star scientists may be attracted by the opportunity to 
conduct research in state-of-the-art facilities within medical schools that provide them 
access to equipment and skilled technicians for their research. They may also be attracted 
by the opportunity to teach at a medical school or participate part time in a clinical practice 
at a hospital. 
                                                 
50 DeVol, Ross, et al. "California’s Position in Technology and Science." Milken Institute: Santa 
Monica (2004): 86. 
51 Wong, Perry, and Armen Bedroussian. "Economic Benefits of Proposed University of Central Florida 
College of Medicine." Santa Monica, CA: Milken Institute (2006). 
52 Zucker, L. G., M. R. Darby, and M. B. Brewer. "Intellectual human capital and the birth of US 
biotechnology enterprises. American Economics Review 88 (1) 290–306." Intellectual Capital and 
Financing Decisions: Evidence from the US Patent Data 23 (1998). 
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A strong college of medicine serves to attract human capital beyond university-
based scientists. Individuals tend to marry others with similar characteristics as themselves 
such as age, education, religion, income, and even physical characteristics such as weight 
and height – a phenomenon known as “assortative mating”.53 Healthcare and bioscience 
clusters such as Medical City can capitalize on this phenomenon by using it as an 
opportunity to attract more qualified professionals for hire. Medical City at Lake Nona 
already offers a centralized job search protocol, making it easier for spouses to identify 
jobs within the cluster and to co-locate. Sanford Burnham president and CEO John Reed 
noted that “the presence of a cluster makes it easier to find a workplace for professional-
level spouses who frequently work in related fields — a surgeon, for example, married to 
a researcher.”54 
Not to be overlooked are the medical school graduates themselves. Physicians 
engage in a variety of activities that enhance the agglomeration effects of life science 
clusters, including relaying patient medical needs and priorities to researchers, 
spearheading technological innovation (e.g. medical devices55), enrolling patients in 
clinical trials, consulting and giving lectures. Physician-scientists (researchers with either 
M.D. or M.D.-Ph.D degrees) are a uniquely valuable component of the biomedical 
workforce, using insight from clinical practice to guide relevant basic discovery research 
and innovation. Deborah German, dean of the UCF College of Medicine, noted the 
                                                 
53 Chiappori, Pierre-André, Sonia Oreffice, and Climent Quintana-Domeque. "Fatter attraction: 
anthropometric and socioeconomic matching on the marriage market." Journal of Political Economy 120.4 
(2012): 659-695. 
54 Howard, Mark R. "Medical City Is Changing Florida's DNA."  Florida Trend, 1 Oct. 2009. Web. 27 Mar. 
2016. <http://www.floridatrend.com/article/4984/medical-city-is-changing-floridas-dna>. 
55 Chatterji, Aaron K., et al. "Physician-industry cooperation in the medical device industry." Health 
Affairs 27.6 (2008): 1532-1543. 
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importance of having both research and clinical foundations, saying that “You don’t want 
a faculty that practiced medicine 20 years ago, or worse, never practiced at all.”56 
While the quality of human capital is important, the sheer number of scientists, 
practitioners, physicians associated with a college of medicine also has implications for 
research productivity. Using a natural experiment in NIH funding during the recession, 
analysts found that research projects with a larger team size (as measured by the number 
of authors) generated more and higher-impact research (as measured by citation rates) that 
was less likely to fail.57 Similarly, a 2006 study by the Milken Institute found that, of the 
top 20 universities ranked by publication output, only one – Rockefeller University - lacked 
a medical school. Rockefeller University does, however have a medical training program 
with an affiliated hospital and an M.D./Ph.D. program with the Graduate School of Medical 
Sciences at Cornell University.58 
 
Adapting to New Research Norms 
The presence of a college of medicine may also help universities adapt to the 
changing trajectory of biomedical innovation. The traditional view of the progress of 
biomedical research - beginning with basic research, followed by applied research and 
finally by commercialization - may no longer hold. Learning through clinical practice and 
technological advancement, for instance, may yield advances in medical diagnosis and 
treatment independent of new discoveries made through basic research.59  Advances made 
                                                 
56 "Lake Nona's Medical City." Spacecoast Business, Apr. 2014. Web. 29 Mar. 2016. 
<http://www.spacecoastbusiness.com/lake-nonas-medical-city/>. 
57 Park, Hyunwoo, Jeongsik Jay Lee, and Byung-Cheol Kim. "Project selection in NIH: A natural 
experiment from ARRA." Research Policy 44.6 (2015): 1145-1159. 
58 DeVol, Ross C., et al. Mind to market: A global analysis of university biotechnology transfer and 
commercialization. Santa Monica, CA: Milken Institute, 2006. 
59 Nelson, Richard R., et al. "How medical know-how progresses." Research Policy 40.10 (2011): 1339-
1344. 
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in non-medical disciplines, including physics, material sciences, mathematics and 
engineering are increasingly important and frequently adapted for biomedical use. In 
addition, universities have been increasingly involved in commercialization activities since 
the Bayh-Doyle Act of 1980 allowed them to own the patents arising from their federal 
research grants rather than assign ownership to the government. Such a blurring of lines 
has altered the role of government, universities, private research institutes and the private 
sector in the trajectory of innovation. 
In light of these changes, universities are expanding their roles beyond that of basic 
research. The presence of a college of medicine enables a university to position itself for 
more translational (i.e. basic to clinical) research by providing access to physicians and 
patients and provides local partners like Sanford Burnham with more opportunities to 
collaborate with clinical faculty. A college of medicine also provides universities with an 
edge in product commercialization by attracting star scientists likely to engage in academic 
entrepreneurship. 
 
 
UCF COLLEGE OF MEDICINE 
The UCF College of Medicine was considered critical for the development of the 
Lake Nona biomedical cluster. Several key partners chose to locate to Lake Nona only after 
the College of Medicine’s presence was secured. The establishment, successes and 
challenges faced by the new school of medicine are explored in the sections below. 
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Establishment 
UCF President John Hitt had long been focused on transforming the Orlando 
economy and diversifying away from its dependence on tourism by developing biotech 
research capability within the region. This focus complemented a larger statewide push for 
technology of the biotechnology industry in Florida begun by the Florida Legislature and 
Governor Jeb Bush. Ironically, a medical school was not part of Hitt’s vision until he 
learned of the range of benefits provided by a college of medicine. That information led 
him to state that “you don’t find a biotech cluster around anything but a medical school”.60 
The structure of the life sciences industry in Orlando prior to 2009 was poised to 
benefit from the presence of a new college of medicine. In 2006 Orlando’s life science 
sector was comprised mainly of medical-device manufacturing firms, with 17 of the top 20 
life science firms engaged primarily in life-science manufacturing.61 Orlando was also 
home to the Burnett Biomedical Research Center and to a large health-care system that 
included Florida Hospital and Orlando Regional Healthcare. The UCF College of Medicine 
was expected to capitalize on the growing relationship among academic, research and 
clinical practice by collaborating with this already strong life science base. 
A 2006 Milken Institute study quantified the anticipated impact of the UCF College 
of Medicine on the greater Orlando economy. Compared to baseline projections, the 
college of medicine was expected to have a minimum economic impact of $1.4 billion and 
create more than 6,000 jobs. In the event that the College of Medicine triggered the growth 
                                                 
60 Howard, Mark R. "The Keys to Medical City." Florida Trend, Oct.-Nov. 2009. Web. 29 Mar. 2016. 
<http://www.floridatrend.com/article/4985/the-keys-to-medical-city>. 
61 "Lake Nona's Medical City." Spacecoast Business, Apr. 2014. Web. 29 Mar. 2016. 
<http://www.spacecoastbusiness.com/lake-nonas-medical-city/>. 
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of the Orlando life sciences industry in a pattern resembling established clusters, its 
economic impact was predicted to be more than $6.4 billion and more than 25,000 jobs. 
In 2005 the Tavistock Group, an international investment organization, fast 
forwarded the development of a medical school in Orlando by donating 50 acres at its Lake 
Nona complex and $12.5 million.  Combined with locally raised funds and a matching 
grant from the state, UCF received well over $100 million in support, and in March 2006 
the Florida Board of Governors approved UCF’s proposal to build a college of medicine. 
The UCF College of Medicine opened its doors to its first class in August of 2009. 
 
Successes to Date 
The announcement of the medical school quickly prompted the hoped-for 
clustering effects.  As soon as the College of Medicine was approved in 2006, Sanford 
Burnham announced its intention to expand operations to Lake Nona. The presence of a 
College of Medicine played a key role in this decision. “History has shown that successful 
biotech hubs have at their core a medical school, which drives scientific exchange and the 
pursuit of knowledge,” noted Dr. John Reed, president and CEO of Sanford Burnham 
Institute, in a release. “The presence of the UCF medical school was an extremely 
important factor in our decision to locate our East Coast campus at Lake Nona.”  
The decision of Sanford Burnham and other partners to locate next door to the 
College of Medicine at Lake Nona was motivated by the highly localized nature of 
knowledge spillovers. Recent research has demonstrated that the benefits of knowledge 
spillovers are strongest within five miles or less, and diminish rapidly with distance.62 Also, 
given the complicated nature of biotechnology discoveries, tacit knowledge is often 
                                                 
62 Buzard, Kristy, et al. "Localized Knowledge Spillovers: Evidence from the Agglomeration of American 
R&D Labs and Patent Data." (2015). 
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embodied in individual scientists, and requires short-distance or face-to-face interactions 
for successful knowledge transfer.63 The geographic proximity of Sanford Burnham and 
other partners to the medical school at Lake Nona allows them the proximity and 
opportunities to interact with researchers at the College of Medicine in order to gain the 
benefits of knowledge spillovers.64  
The Lake Nona clustering effect continued beyond Sanford Burnham, as a series of 
major partners announced their intention to join Lake Nona alongside the UCF College of 
Medicine and Sanford Burnham. The Department of Veterans Affairs, which had 
considered several sites for the construction of its first new hospital since 1995, finalized 
its decision to locate at Lake Nona soon after Sanford Burnham.65 Nemours Children’s 
Hospital, which had already purchased land for a hospital elsewhere, changed its mind 
within months of these announcements and in 2007 revealed its intention to build a 
pediatric center at Lake Nona.66 A commitment from the M.D. Anderson Cancer Center 
followed that same year, and in 2008 the University of Florida announced plans to locate 
an academic and research facility at Medical City.   
The UCF College of Medicine received over 4,300 applications for 41 positions in 
its charter class, making it the most selective medical school in the United States at that 
time. This initial class had the highest MCAT score (32.2) and GPA (3.8) of any incoming 
                                                 
63 Zucker, Lynne G., Michael R. Darby, and Jeff S. Armstrong. "Commercializing knowledge: University 
science, knowledge capture, and firm performance in biotechnology." Management Science 48.1 (2002): 
138-153. 
64 Carlino, Gerald A., and Jake K. Carr. "Clusters of knowledge: R&D proximity and the spillover 
effect." Business Review Q3 (2013): 11-22. 
65 "House OKs VA Hospital at Lake Nona." Orlando Business Journal, 13 Sept. 2006. Web. 30 Mar. 2016. 
<http://www.bizjournals.com/orlando/stories/2006/09/11/daily29.html>. 
66 Boyd, Christopher. "Nemours Adds Lake Nona to Its List." Orlando Sentinel, 7 Oct. 2006. Web. 30 Mar. 
2016. <http://articles.orlandosentinel.com/2006-10-07/news/NEMOURS07_1_nemours-children-hospital-
florida-hospital>. 
 53 
class of medical students in Florida.67  The flood of applications was due in part to the fact 
that every member of the inaugural class was guaranteed a full scholarship, including 
tuition and living expenses. However, acceptance continued to remain competitive for 
future classes, which were not offered such benefits. UCF received a record 4,875 
applications for the recently accepted Class of 2019 – even more than it received for the 
charter class. 
 
Challenges to Date 
Despite initial success in promoting clustering at Lake Nona and the competitive 
profile of its medical students, UCF’s College of Medicine has been slow to solidify its 
reputation and expertise in biomedical research. It remained unranked in U.S. News’ 2016 
ranking of medical schools in both research and primary care categories, implying that it 
was in the bottom 25% of both categories. The college gained accreditation only in 
February of 2013, just before the graduation of its first class.  
Funding for UCF was also slow to launch. Additional NIH Funding attracted by the 
college, for example, has been minimal. Through 2007 the NIH Research Portfolio Online 
Reporting Tool reported “Overall Medical” funding for the University of Central Florida 
– although it is unclear which departments this funding is associated with, it is not directly 
associated with the College of Medicine which was not even approved until 2006. 
Beginning in 2008, NIH began reporting funding directly associated with the College of 
Medicine and the “Overall Medical” funding category disappeared. It can be reasonably 
assumed, then, that the College of Medicine funding amounts included grants which would 
prior of fallen under “Overall Medical” funding. The ability of the College of Medicine, 
                                                 
67 "No. 1 UCF Story of the Decade: College of Medicine." UCF Today. University of Central Florida, 3 
Aug. 2009. Web. 30 Mar. 2016. <http://today.ucf.edu/no-1-ucf-story-of-the-decade-is/>. 
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therefore, should be viewed as the difference between “Overall Medical” funding trends 
and funding formally listed under the “College of Medicine” beginning in 2008. 
Importantly, this difference is minimal. In 2007, for instance, “Overall Medical” funding 
for UCF totaled $4.7 million. In 2008, the amount associated with the College of Medicine 
was  $5.5 million – a difference of only $0.8 million. This funding level increased slowly 
through 2011, and has fallen since. In 2015, for instance, total NIH funding for the UCF 
College of Medicine was a mere $3.5 million. Clearly, the College of Medicine has been 
slow to attract research funding. 
This limited research is not surprising, however, given how new the college is. The 
Burnett School of Biomedical Sciences (which was subsumed by the College of Medicine), 
did provide a foundation of biomedical expertise and resources for the College of 
Medicine, but was itself only established in 2004. Indeed, although the UCF College of 
Medicine is expected to serve as the anchor for Medical City, the college itself depended 
on collaboration with strategic partners to accelerate its transition from a nascent to a strong 
research-oriented medical school. These partners, however, were slow to cement their 
presence at Medical City, possibly delaying the college’s ability to catalyze the life science 
industry at Medical City and in the Orlando region more broadly. Despite the initial flurry 
of activity in 2006 as partners announced their intentions to locate to Lake Nona, nothing 
actually opened until 2009. The College of Medicine itself - although it welcomed its first 
class in 2009 - did not open its building to students until a year later in 2010. The Burnett 
School of Biomedical Sciences, M.D. Anderson and Sanford Burnham were the first of the 
key Medical City partners to open in 2009.68  Nemours Children’s Hospital and the UF 
Academic and Research Center did not open until late 2012, more than four years after 
                                                 
68 Because of ties with another hospital in Florida, which located downtown instead of in Medical City, 
MD Anderson no longer has a physical presence at Lake Nona. 
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their commitments. The huge VA hospital, which broke ground in 2008 and was initially 
expected to be completed in 2012, still is not fully operational (although some services 
opened in 2015).69 The timeline below outlines the commitments and opening of key 
partners at Lake Nona. 
 
Table 3: Timeline of the Development of Lake Nona 
2006 Florida Board of Governors approves UCF medical school 
Sanford Burnham announces intention to open office at LN 
2007 Nemours announces its intention to locate at LN 
Veterans Affairs announces intention to build new VA hospital 
 MD Anderson commits to locate at LN 
2008 UF announces intention to open academic and medical facilities 
2009 UCF College of Medicine welcomes first class 
Sanford Burnham Institute officially opens 
MD Anderson opens 
2010 College of Medicine building opens 
2011 - 
2012 Nemours Children’s Hospital Opens 
UF academic and research centers open 
2013 - 
2014 - 
2015 MD Anderson leaves Lake Nona 
VA begins operating some services, though is not fully operational 
                                                 
69 "Orlando VA Hospital Opens Years Behind Schedule." WESH.com, 26 May 2015. Web. 30 Mar. 2016. 
<http://www.wesh.com/health/dedication-planned-for-new-orlando-va-hospital/33202944>. 
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PROSPECTS FOR FUTURE PERFORMANCE 
UCF’s focus on building the academic infrastructure for a preeminent medical 
school, an unexpected drop in R&D funding in light of the Great Recession, and the slow 
progress of some partners in cementing a physical presence at Lake Nona may have limited 
the development of the college as well as the extent of its interaction with the life science 
industry in Orlando. Future collaboration, however, is likely to be more productive. The 
recent accreditation of the College of Medicine, for instance, is likely to attract higher 
skilled medical students now that applicants can be certain they will graduate with a degree 
that will translate to the workplace. Rebounding levels of NIH funding will serve to fuel 
the activities of researchers within the college. As UCF builds its reputation, it will exert 
an additional pull for new/smaller life science firms concerned with overcoming the 
“liability of newness” by benefiting from the legitimacy spillovers of a reputable college 
of medicine.  
Other partners key to the success at Lake Nona are finally establishing a physical 
and research presence. The VA Hospital, for instance, began offering a limited set of 
services in 2015 and is expected to fully open in 2016. As partners cement their presence 
at Lake Nona collaboration is likely to increase. UCF is also taking extra steps to encourage 
the development of Lake Nona by locating all of its allied health efforts at the cluster, 
including moving the dental and nursing school. Their presence will further provide a 
strong opportunity for synergistic research and collaboration for the College of Medicine. 
As the national and state economies continue to recover from the Great Recession, 
the College of Medicine can also look forward to increasing funding for basic research 
efforts. In 2016, for instance, bipartisan support for biomedical research led to an increase 
in total appropriations for NIH of $2.2 billion – a 12% increase over 2015 funding levels 
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and the largest increase in appropriations in over 10 years (refer to Chapter 5 for detailed 
discussion on NIH funding trends and opportunities). 
In sum, although a College of Medicine was considered crucial to the successful 
development of Lake Nona, the slow development of the new school has likely stunted the 
development of the cluster as a whole. As other partners at Lake Nona independently gain 
strength and biomedical funding rebounds, supporters of the Lake Nona development may 
have grounds to hope that the college will prove to be the catalyst it was anticipated to be 
in early studies by the Milken Institute. There is, however, no assurance of such a recovery 
and if the College remains weak it will be much to the detriment of the hoped-for cluster. 
Given the slow development, Lake Nona’s development has rested more heavily 
than expected on the initiatives and research of other key partners such as the Sanford 
Burnham Institute.  Given the increasingly interdisciplinary nature of biotechnology and 
life science research, the UCF system as a whole would have played an important role in 
providing the benefits of an academic anchor institution for the cluster. The next section 
will analyze the strengths of the UCF system as a whole in understanding whether the 
university has been a strong complementary partner for the Lake Nona complex as it waits 
for the College of Medicine to gain strength. 
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Chapter 7: Strength of the University of Central Florida 
Given the slow start of the UCF College of Medicine, the role of UCF system more broadly 
in fostering a biomedical cluster at Lake Nona was more important than originally 
anticipated. This chapter looks at the quality of the UCF system (by analyzing rankings) 
and funding strength in order to understand whether the university has been a strong partner 
over the past decade which could have compensated for a lack of resources Lake Nona 
supporters would have viewed as critical – including NIH funding, venture capital funding, 
and the UCF College of Medicine. 
 
INTRODUCTION 
While the presence of a strong medical school is an important complement to the 
development of biotech clusters, clusters also benefit from having access to the university 
system more broadly. Given the slow development of the UCF College of Medicine as a 
research partner, as described in the previous section, Sanford Burnham may rely more 
heavily than anticipated on agglomeration benefits provided by the UCF system as a whole. 
The following sections analyze the academic standing of the UCF with respect to funding 
as well as funding trends and prospects in order to understand its potential to support 
through collaboration the research efforts of Sanford Burnham and at Lake Nona. 
Medical research in the US began to organize itself closer to university 
communities in the 1950s as the life sciences became increasingly complemented by 
innovations in the physical sciences, engineering and computer sciences.70. Medical 
devices and new manufacturing practices for large-molecule bio-pharmaceuticals, for 
                                                 
70 Rosenberg, Nathan. "Some critical episodes in the progress of medical innovation: An Anglo-American 
perspective." Research Policy 38.2 (2009): 234-242. 
 59 
instance, are heavily driven by engineering advances, which depend more on the physical 
sciences and less on the biological sciences. X-rays, electron microscopy, endoscopy and 
the CT scanner are but a few examples of medical technologies that emerged from research 
in physics. In addition, a strong undergraduate population provides clusters with access to 
high skilled labor, university faculty often serve as consultants in biotech firms and 
innovations outside of medical research are resources for biotechnology clusters. 
 
RANKINGS 
Although the methodologies of rankings systems vary and are imperfect, they 
provide a useful independent third party assessment of UCF’s strengths across disciplines. 
Student-oriented rankings were de-emphasized in favor of academic rankings, including 
the ARWU (Shanghai), Leiden, and MUP. U.S. News rankings are also analyzed briefly 
given their popularity. 
Although the ranking systems referenced in this paper differ widely in their 
methodologies, several patterns emerge. UCF is consistently ranked among the top 300-
400 universities in the world and among the top 100-150 universities nationally. Field 
specific rankings demonstrate a relative strength in the physical and engineering sciences 
and, to a lesser extent, in the social sciences. While ARWU, Leiden and U.S. News 
rankings indicate that the quality of UCF’s research in the biomedical and health fields 
remains relatively weak in comparison to other universities, the Leiden rankings show that 
the quantity of research in this area has been increasing slowly. Although UCF tends to 
rank low on indicators of faculty prestige, its undergraduate population is of high quality 
and improving.  
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ARWU Rankings 
The Academic Ranking of World Universities (ARWU), commonly referred to as 
the Shanghai Ranking, is a global ranking of universities produced annually since 2003 by 
the Center for World Class Universities of Shanghai Jiao Tong University. Over 1,200 
universities are ranked by ARWU every year, and the overall ranking of the top 500 
universities are published. The exact ranking of the top 100 universities is provided, while 
a ranked range is provided for the other 400 top institutions. Impressively, UCF has 
consistently earned a place among ARWU’s top 500 universities since 2003, rising steadily 
in both global and national rankings from 2003 through 2013, with a small dip in its ranking 
in the last two years. 
 
Table 4: UCF Placement in Annual ARWU Rankings 
 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
World 
Rank 
401-
500 
404-
502 
401-
500 
301-
400 
305-
402 
303-
401 
201-
302 
201-
300 
201-
300 
201-
300 
201-
300 
301-
400 
301-
400 
National 
Rank 
UR UR 
141-
168 
119-
140 
118-
140 
115-
139 
91-
112 
90-
111 
90-
110 
86-
109 
86-
108 
105-
125 
103-
125 
UR: Unranked 
 
Although ARWU does not provide the final weighted scores or exact rankings for 
all institutions, it does provide institutions’ scores on each of the six indicators used to 
arrive at the final overall score. These indicators include including; i) the number of staff 
winning Nobel Prizes and Fields Medals; ii) the number of alumni winning Nobel Prizes 
and Fields Medals; iii) the number of highly cited researchers as determined by Thomson 
Reuters (HiSi); iv) the number of papers published in Nature and Science (N&S); v) the 
number of papers indexed in major science and social science citation indices (PUB), and; 
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vi) the per capita academic performance of an institution (PCP). For each of these six 
indicators, the highest scoring institution is assigned a score of 100, and other institutions 
are calculated as a percentage of the top score.  
By tracing UCF’s scores on each of these indicators over time, we gain a sense of 
UCF’s performance relative to the highest ranking university (consistently Harvard) and 
which of the six indicators play a role in carrying UCF in ARWU’s rankings. While the 
UCF has earned a score of 0 with respect to alumni and staff awards relative to Harvard, 
UCF’s relative research output and its number of highly cited researchers have allowed the 
university to maintain its position in the ARWU rankings. In particular, the number of 
publications in Nature and Science has risen steadily since 2005, driving the rise of PCP 
indicator and likely the overall ranking of UCF. 
 
Figure 6: UCF Relative Scores on ARWU Ranking Indicators 
 
 
To complement their overall ranking, ARWU also developed rankings by subject 
for the top 200 universities using a methodology similar to that used to compute the overall 
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rank. As seen in the table above, UCF has frequently ranked among the top 200 universities 
in Engineering and Social Sciences fields. Engineering in particular is a strong subject area 
for UCF, as the school has ranked among the top 150 universities in the world four times 
since 2007.  
 
Table 5: UCF Placement in Annual ARWU Global Rankings by Subject71 
 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Natural Science & 
Mathematics 
- - - - - - - - - 
Engineering, 
Technology & 
Computer Science 
77-
106 
- - 
76-
100 
- 
101-
150 
101-
150 
- - 
Life & 
Agricultural 
Sciences 
- - - - - - - - - 
Clinical Medicine 
& Pharmacy 
- - - - - - - - - 
Social Sciences - - - - - 151-
200 
- - 
151-
200 
 
Overall, the ARWU rankings indicate that UCF’s performance has been steadily 
improving since 2003, placing it among the top 500 universities globally and top 200 
nationally. UCF’s performance in the sciences, particularly the number of scientific 
publications, seems to be driving its rankings, with a particular strength in engineering and 
social sciences, while historical prestige of alumni and students has held it back. 
                                                 
71 Given that ARWU only published the ranks of the top 200 universities, the absence of a rank in the table 
above indicates that UCF was not among the top 200 universities in that field. 
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Leiden Rankings 
In addition to ARWU, the Leiden Rankings were analyzed in order to gain a better 
understanding of UCF’s strengths by discipline. The Leiden rankings are an annual global 
university ranking based on the volume and citation impact of publications found in the 
Web of Science database. Rankings are published for the 750 universities with the highest 
publication output. Leiden publishes two sets of rankings. The size dependent ranking 
ranks universities on the total number of scientific publications, as well as the number of 
publications which fall into the top 50%, 10% and 1% of their field (based on citations). In 
an attempt to correct for institutional size and better reflect the quality of a university’s 
publications, size independent rankings are provided based on the proportion of a 
university’s publications that fall into the top 50%, 10% and 1% of their field. UCF’s 2015 
rankings are provided in Table 6 for both sets of rankings. 
 
Table 6: UCF’s Overall and Field Specific Global Rank by Leiden 
 
 
In 2015 UCF ranked 331st with respect to the total number of scientific publications 
which were considered among the top 10% in their fields. When publication volume is 
controlled for, UCF’s overall rises in rank to 249th, indicating the high quality of its 
publications. Although UCF does not display a particular strength in the biomedical 
Total Top 50% Top 10% Top 1% Top 50% Top 10% Top 1%
All Sciences 382 356 331 333 305 249 267
Biomedical & Health Sciences 526 497 485 573 345 396 571
Life & Earth Sciences 493 490 418 330 411 265 158
Mathematics & Computer Science 258 281 279 435 426 333 476
Physical Sciences & Engineering 249 229 191 152 157 126 112
Social Sciences & Humanities 188 302 216 302 241 307 364
Size Dependent Rank Size Independent Rank
Field
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sciences and earth sciences in terms of the number of highly cited publications, its rank in 
both fields rises by over 100 spots in the size independent ranking system. Of particular 
note is UCF’s performance in the physical and engineering sciences, where it ranks among 
the top 150-200 universities in both ranking sets.  
UCF’s strength in physical and engineering sciences relative to other universities 
is underscored by its internal focus on research in this area. As seen in chart X, UCF 
publishes more papers in the physical and engineering sciences than any other field, with 
43% of the institution’s total publications categorized in these disciplines between 2010 
and 2013. 
 
Figure 7: UCF Publication Output by Science Field (2010-2013) 
 
 
Although engineering remained the largest research area for UCF throughout all 
four Leiden rankings, the fastest growing research area within the university has been in 
Biomedical & 
Health
470
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Life & Earth
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Math & Computer
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410
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Physical and 
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1071
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biomedicine and health. In between 2006 and 2009, biomedical publications accounted for 
15.2% of UCF publications; within three years, this had risen to nearly 19% while the 
relative proportion of publications in engineering and math fell slightly. Given that the 
Burnett College of Biomedical Sciences was not established until 2004 and the College of 
Medicine (which subsumed the Burnett College) was not established until 2006, this rise 
in biomedical research output may directly reflect the growing strength and focus of the 
new medical school. Size independent rankings, however, show that the proportion of UCF 
biomedical publications belonging to the top 10% of their field has remained relatively 
constant, at 8-9%. 
 
MUP Rankings 
Between 2001 and 2013 the Center for Measuring University Performance (MUP) 
produced an annual ranking of the top U.S. research universities based on nine measures 
selected to reflect their research, resources, faculty performance, and education quality. In 
2011, UCF ranked 107th in the country among all major U.S. research universities.72 
Unfortunately, UCF’s overall ranking by MUP cannot be traced over time as a comparable 
overall ranking was only provided for the top 50 institutions in other reports. However, 
exhaustive sub-rankings were provided for each of the indicators used to arrive at the 
overall ranking, providing further insight into UCF’s strengths and weaknesses. 
Because federal research funding is peer reviewed and the competition is conducted 
on an open nationwide basis, it is widely considered a good indicator of the quality of 
university faculty and research. In 2000 UCF ranked 188th among all U.S. universities with 
respect to federal research funding and 131st amongst public universities; by 2011 these 
                                                 
72 For 2011, MUP report defined “major research universities” as all universities with a federal research 
expenditure of over $40 million; 137 institutions met this criterion in 2011. 
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ranks had risen to 137th and 97th respectively, indicating a rise in both the quality and the 
quantity of research output. 
Similar to the ARWU rankings, UCF does not perform well on measures of faculty 
performance and prestige. MUP counts the number of National Academy members and the 
number of prestigious awards received by faculty in order to assess an institution’s ability 
to recruit and retain competitive faculty members.  In 2012, only one UCF professor was a 
member of the National Academy; in contrast, the public institution with the largest 
number of National Academy presence had 230 members. Similarly, UCF faculty earned 
seven prestigious faculty awards compared to 45 at the public university ranking highest 
on this indicator. 
In order to assess the quality of undergraduate programs, MUP considers the total 
number of National Merit Scholars attending an institution as well as the average entering 
SAT score (reading and math) of freshman. In 2012, UCF attracted 68 National Merit 
scholars, ranking 32nd among all universities and 13th among all public institutions. With a 
median SAT score in 2011 of 1185, UCF ranked 220th among all U.S. universities and 57th 
among public universities, rising 94 and 18 spots respectively since 2003 when the median 
score was 45 points lower. A look at UCF’s website shows that the quality of the 
undergraduate class has continued to improve, with average SAT scores rising 13 points 
between 2013 and 2015 and the average high school GPA rising from 3.89 to 4.0.73,74 An 
exploratory ranking by MUP in their 2013 report underscores the strength of UCF 
educational programs: in a ranking based solely on educational indicators (doctorates 
awarded and median SAT scores), UCF rose from 107th to 82nd in an overall ranking of all 
                                                 
73 "Freshman Applicants." University of, n.d. Web. 30 Mar. 2016. 
<https://admissions.ucf.edu/apply/freshman>. 
74 Postal, Leslie. "UCF Enrollment Tops 60,100." Orlando Sentinel, 4 Sept. 2013. Web. 30 Mar. 2016. 
<http://www.orlandosentinel.com/features/education/school-zone/os-ucf-enrollment-record-post.html>. 
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U.S. universities (both public and private). In addition to increasing access to skilled labor 
in the Orlando area, this rising undergraduate profile may be a significant asset in recruiting 
and retaining highly productive faculty and staff. 
 
A. U.S. News Rankings 
U.S. News and World Report education rankings ranked UCF 168th overall among 
national universities and 91st among public universities in 2016. UCF was also recognized 
as the 13th “Most Innovative School” in the nation based on college officials’ opinions of 
which universities were making the most innovative improvements in terms of curriculum, 
faculty, students, campus life, technology and facilities. UCF’s College of Medicine, 
however, has remained unranked by U.S. News’ assessment of the best medical schools, 
implying that it was in the bottom 25% in both research and primary care. 
 
UCF FUNDING 
The above analysis of UCF rankings demonstrates a strong university partner 
poised to provide the Orlando biotech community with opportunities for collaborative 
research and access to a pool of highly skilled students. However, decreases in funding 
following the 2008 economic crisis have placed UCF in a very different financial position 
than would have been predicted at the time Sanford Burnham decided to join Lake Nona. 
Efforts to increase tuition and total enrollment numbers have not made up for cutbacks in 
state funding, resulting in low levels of funding per FTE at UCF. Assuming constant costs 
per FTE, these falling funding levels would have limited resources remaining for research 
efforts and thus the development of UCF’s biomedical research capacity. 
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State Funding 
 Between 2007 and 2012 total education and general (E&G) state appropriations 
for the State University System of Florida (SUS) fell by more than 38%, making it the state 
with the second largest funding decrease in the nation during those years.75  UCF was not 
immune to this trend; as shown in Figure 8, educational appropriations per FTE at UCF 
fell from $7,174 in 2006 to a low of $3,234 in 2012 – a 55% decrease.  
 
Figure 8: UCF FTE Enrollment & Total Revenue per FTW by Funding Source     
(constant 2009$) 
 
 
Prior to the financial crisis, Florida universities had received consistent financial 
support from the state since the early 1990s (though funding growth did stall in the early 
2000s, in part due to the brief 2001 recession). The trend line in Figure 9 demonstrates 
what total state funding per FTE would have been at UCF had it continued to rise at the 
                                                 
75 Malcolm, Hadley, and Sean McMinn. "Sagging State Funding Jacks up College Tuition." USA Today. 3 
Sept. 2013. Web. <http://www.usatoday.com/story/money/personalfinance/2013/09/02/state-funding-
declines-raise-tuition/2707837/>. 
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1993-2006 trend rate (a trend Sanford Burnham would likely have anticipated when it made 
the decision in 2005 to establish itself in Orlando).  In FY 2012, state funding per UCF 
FTE had fallen to $3,234 – nearly 60% below a funding level of $7,738 per FTE which 
could have been estimated from 1993-2006 funding trends. Although state funding for 
universities began to rise in 2013 as the state economy recovered from the recession, state 
funding per FTE at UCF in 2014 remained 36% below trend. 
 
Figure 9: Predicted vs. Actual UCF State Funding per FTW (constant 2009 $) 
 
 
Tuition Revenue 
Universities throughout Florida, including UCF, resorted to a number of strategies 
in order to compensate for falling state funding, including raising tuition within limits set 
by the Florida legislature. Under Governor Charlie Crist, a number of changes in Florida 
law allowed Florida universities to raise tuition rates during the recession more 
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dramatically than ever before.76 Prior to 2009, the legislature set undergraduate tuition 
rates, and the Board of Governors set graduate and out-of-state rates. Beginning in 2009, 
the legislature allowed the Board of Governors to raise undergraduate tuition rates (at a 
rate called the tuition differential) beyond the base rate increase approved by the 
legislature, as long as the sum of the two increases did not raise tuition by more than 15%. 
In its requests to the Board of Governors, UCF attempted to maximize total tuition 
increases by requesting a tuition differential that would raise tuition by the cap of 15% 
when combined with the legislative base increase.77 Indeed, between 2009 and 2011, the 
sum of the base increase and the tuition differential for the state of Florida reached the cap 
of 15%.   
As seen in the graph below, real tuition revenues per FTE at UCF increased rapidly 
beginning in FY2009 as UCF took advantage of its ability to raise tuition. In FY 2012, real 
tuition revenue per FTE was 51% higher than FY 2008 compared to a 13% increase which 
would have been predicted had tuition revenue per FTE continued to rise at the 1993-2006 
trend.  
Governor Rick Scott (who entered office in 2011) is largely opposed to raising 
tuition rates and has used his influence with the legislature and Board of Governors to limit 
increases since 2012. In 2013, tuition increases were automatically capped at the rate of 
inflation after Scott vetoed a legislative increase and influenced the Board of Governors to 
set a tuition differential of zero percent. In 2014, the tuition differential process was 
scrapped entirely and the provision for a minimum automatic tuition increase set at the rate 
of inflation was eliminated. These limitations on tuition growth for UCF are reflected in 
                                                 
76 Gillin, Joshua. "Rick Scott Says Charlie Crist Let Tuition Increase 5% Ever Year." Politifact Flrida, 4 
June 2014. Web. 20 Mar. 2016. <http://www.politifact.com/florida/statements/2014/jun/04/rick-
scott/charlie-crist-allowed-college-tuition-increase-15-/>. 
77 Tuition Differential Fee Reports, State University System of Florida 
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Figure 10, as tuition revenue per FTE returns to growing at previous trend rates. However, 
during Charlie Crist’s administration, UCF tuition revenue per FTE remained 27% higher 
than could have been predicted otherwise. 
 
Figure 10: Predicted vs. Actual UCF Tuition per FTE (constant 2009 $) 
 
Tuition hikes by Florida universities, however, could not compensate for plunging 
state funding. This was due to the fact that Florida tuition rates were extremely low to begin 
with. In 2007, immediately before the crisis, the average published tuition and fees of 
public four-year institutions in Florida were the lowest in the nation.78 As a consequence, 
although tuition grew at a rapid rate, the absolute increase in tuition revenues was small 
and total funding per FTE remained low (see Figure 11 below).  Indeed, total revenue per 
FTE at UCF fell each year between 2006 and 2012 despite annual tuition increases. 
 
 
                                                 
78 Trends in College Pricing 2015. Rep. The College Board. Web. 18 Apr. 2016. 
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Figure 11: Predicted vs. Actual UCF Total Funding per FTW (constant 2009 $) 
 
Although total funding per FTE began to rebound in 2013 as the national economy 
and state funding has recovered, total funding per FTE at UCF remained 14.5% lower in 
2014 than would have been predicted had it risen at the 1993-2006 trend rate. 
 
Stalling FTE Enrollment and Tuition Revenue 
Prior to the economic crisis, UCF had long been pursuing a strategy of rapidly 
increasing enrollment rates. According to the National Center for Education Statistics’ 
Integrated Postsecondary Education Data System, between 1993 and 2008 total student 
enrollment increased by 112%, from 23,692 to 50,121, making UCF the second largest 
four year university in the U.S. (after Arizona State University) and the largest in Florida. 
John Hitt, UCF’s president since 1992, has overseen this explosive growth and has not 
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shown an interest placing limits on enrollment, asserting in a recent interview that it’s 
possible for a university to be both “big and good”.79 
In response to falling funding levels during the economic crisis, enrollment rose at 
universities as the opportunity cost of going to school fell relative to work opportunities. 
Indeed, many universities actually made a concerted effort to increase enrollment in an 
attempt to attract proportionally more state funding. These two trends boosted UCF’s 
already high enrollment rates. As seen in the graph below, enrollment between 2009 and 
2012 rose more rapidly than would have been anticipated. In 2011, enrollment was 6.6% 
higher than would have been predicted by 1992-2007 trends. Enrollment rates, however, 
appear to have slowed in 2013, returning to total enrollment prior trend levels as the 
economy and state funding for universities began to rebound. 
 
Figure 12: UCF Total Enrollment 
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It is important to note however, that state funding for universities correlates with 
full time equivalents (FTEs), not necessarily total enrollment. An analysis of UCF FTE 
enrollment during the recession shows that although FTE enrollment also rose faster than 
would have been anticipated based on 1992-2007 trends, it rose at a slower rate than total 
enrollment, implying that UCF was enrolling part-time students at a faster rate than full-
time students. This is confirmed in the following graph presenting the total number of 
students enrolled per FTE at UCF between 1992 and 2014. This ratio began an upward 
trend beginning in 2008 after falling steadily for over fifteen years. 
 
Figure 13: UCF Students per FTE 
 
 
UCF has continued to enroll part-time students at a faster rate than full-time 
students, even as increases in total enrollment have fallen in the last two years. As a result, 
there has essentially been zero growth in total FTE enrollment between 2011 and 2014, as 
seen in the graph below. 
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Figure 14: UCF FTE Enrollment 
 
Thus, although UCF enrollment rose during the recession, FTE enrollment did not 
rise as quickly, likely limiting its ability to attract state funding and raise additional funding 
throughout during the Great Recession. 
 
Future Funding Prospects 
UCF funding per FTE began falling immediately after UCF established itself at 
Lake Nona. Assuming costs per FTE remained constant, this drop would have limited 
UCF’s ability to develop its biomedical research capacity and thus to partner with and 
accelerate the development of the Lake Nona research community. The fall in funding 
levels was most directly attributable to the large decrease in state appropriations for the 
Florida university system. A combination of increased tuition and increased enrollment 
was unable to offset this funding fall for reasons discussed above.  
Fortunately, state funding has risen rapidly as the Florida economy has recovered 
from the Great Recession. Between 2012 and 2014 alone, total real state funding increased 
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by 55%.  As state funding continues to recover and as UCF enrollment falls back to pre-
recession growth rates, funding per FTE will continue to rise, providing resources for 
research, including collaboration with Sanford Burnham.  
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Chapter 8: Conclusion 
The policy-driven industrial cluster at Lake Nona was a result of the aggressive efforts of 
the state of Florida under Governor Jeb Bush and the vision of the Tavistock Group. The 
cluster, however, has failed to yield the anticipated economic impact for Orlando as 
heralded by early supporters and related studies. This paper sought to understand the 
reasons for the muted success of the planned cluster by conducting comparative qualitative 
case studies with other clusters and analyzing trends in factors considered key to the 
success of any biotechnology cluster, including the availability of basic and translational 
funding (i.e. NIH funding and venture capital) and the strength and contributions of the 
University of Central Florida – considered a key anchor institution for the cluster’s 
development. Findings reveal: 
 
 An eight-year development timeline was optimistic given the path-dependent 
development of leading U.S. biotechnology clusters. Although there is no one 
recipe for cluster development based on qualitative case studies conducted, it is 
evident that even with local support, key clusters in the U.S. took decades – if not 
centuries – to develop. New clusters such as Lake Nona must struggle not only to 
overcome such a traditional timeline, but compete with these established clusters 
for resources such as venture capital and skilled labor. However, if other challenges 
listed below are overcome by Lake Nona, advancements in areas such as 
transportation and communication may allow the region to develop more quickly 
than its predecessors. 
 Venture capital has been harder to access than expected at Lake Nona’s 
founding due to the Great Recession. Following the great recession, venture 
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capital resources fell across the board. As the economy has recovered and funding 
for the biotechnology industry has rebounded, venture capitalists have maintained 
their risk aversion and concentrated their investments on older, more established 
firms. This would inhibit the development of translational research, spinoffs, and a 
thriving industrial cluster at new biotechnology centers such as Lake Nona. Chapter 
4 made a few suggestions as to how policymakers at the federal level could take 
steps to encourage venture capital flows to new establishments. However, barring \ 
dramatic shifts in the risk-tolerance of the venture capital industry, aspiring clusters 
like Lake Nona will continue to face a challenge in attracting adequate venture 
capital in order to fuel the commercialization of biomedical discoveries. 
 NIH funding fell dramatically during the Great Recession, inhibiting basic 
research efforts at Lake Nona which were considered critical to the cluster’s 
success.  Lake Nona visionaries could not have planned for the Great Recession or 
the dramatic fall in public research funding that accompanied it. NIH funding levels 
in 2015 were nearly 20% below what developers would have imagined had funding 
continued to increase at historical levels. Anchor institutions focused on basic 
research such as UCF and key partners such as Sanford Burnham would have been 
unable to contribute to the cluster’s development as anticipated. However, 
Congress has displayed an interest in reversing this trend in in recent legislation. 
Such a renewed focus on the life sciences is likely to continue given demographic 
shifts and advancements in technology (as mentioned in Chapter 5) and possibly 
allow the Lake Nona cluster to regain development momentum. 
 The College of Medicine – considered the anchor institution and central to 
Lake Nona’s development – has proved to be a weak partner. The UCF College 
of Medicine has failed to provide the human capital or serve as the funding magnet 
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anticipated. Despite lofty goals, the less than stellar reputation of the college is 
unlikely to change given this poor start and strong competition from other 
preeminent colleges. A weak college of medicine will continue to deter future 
members from joining the cluster, weaken networking effects and discourage 
partners who located to the area based on opportunities for future collaboration with 
the college. 
 In light of the weak academic and research support from the College of 
Medicine, the University of Central Florida more broadly has served as a 
supportive research partner, though UCF itself has been weakened by the 
recent recession and could not have compensated for the weak College of 
Medicine.  Although UCF boasts strengths in academic areas which are 
increasingly complementary to the biosciences – such as engineering and computer 
sciences – the school has witnessed a fall in enrollment and funding which would 
have weakened its ability to compensate for the weakness of the new College of 
Medicine. Although UCF is likely to regain strength as the national economy pulls 
away from the impact of the recent economic crisis, it is unlikely to ever fill the gap 
presented by the weak College of Medicine. 
 
In sum, projections for the rapid development and success of Lake Nona were optimistic 
to begin with. The Great Recession posed challenges to partners and funding that further 
slowed the development of the cluster. Although basic research funding is likely to rebound 
in the future, key challenges such as access to venture capital and the strength of key 
partners are unlikely to be solved anytime soon. In light of such discoveries, Lake Nona 
stakeholders should remove pressure for immediate performance and instead turn their 
focus towards a longer term vision for success.  
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